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ABSTRACT 
The task of comparing and evaluating the performance of different computer-based 
clinical protocols is difficult and expensive to accomplish. This dissertation explores 
methods to compare and evaluate computer-based insulin infusion protocols based on an 
in silico analytical framework iteratively developed for this study, using data from the 
intensive care unit (ICU). In Methods for Aim 1, we used a pairwise comparative technique 
to evaluate two computer-based insulin infusion protocols. Our result showed that the 
pairwise method can rapidly identify a promising computer-based clinical protocol but with 
limitations. In Methods for Aim 2, we used a ranking strategy to evaluate six computer-
based insulin infusion protocols. The ranking method enabled us to overcome a key 
limitation in Methods for Aim 1, making it possible to compare multiple computer-based 
clinical protocols simultaneously. In Methods for Aim 3, we developed a more 
comprehensive in silico method based on multiple-criteria decision analysis that included 
user-defined performance evaluation criteria examining different facets of the computer-
based insulin infusion protocols. The in silico method appears to be an efficient way for 
identifying promising computer-based clinical protocols suitable for clinical evaluation. 
We discuss the advantages and disadvantages for each of the presented methods. We also 
discuss future research work and the generalizability of the framework to other potential 
clinical areas. 
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This dissertation addressed some of the issues that healthcare practitioners face when 
comparing and evaluating computer-based clinical protocols for bedside use and research 
purposes. With the advent of high-performance computing, computer-based clinical 
protocols can be evaluated in a computer-simulated environment. Computer simulation has 
the ability to reproduce the behavior of a system or analyze complex processes safely. 
Healthcare practitioners can use computer simulations to explore issues, gain new insights, 
and analyze the performance of a system without directly affecting their patients. This 
dissertation proposes a framework to develop an in silico method to identify promising 
computer-based protocols for clinical study. 
1.1 Statement of the Problem 
The rising cost of healthcare, fueled by increased demand for better care, has urged 
many healthcare practitioners to seek more effective tools for improving clinical care 
practice [1–4]. Computer-based clinical protocols offer the possibilities of a wider 
dissemination and effective use of evidence-based guidelines and clinical protocols while 
reducing variation in the treatment of patients [5–8]. Extensive developments in multiple 
healthcare institutions have resulted in an increase in the number of computer-based 
clinical protocols available to healthcare practitioners. For example, computer-based 




healthcare practitioners attempt to select a computer-based clinical protocol that will be 
suitable for their practice, they may have concerns such as which computer-based clinical 
protocol performs better or safer. Current strategy for comparing computer-based clinical 
protocols is to implement these protocols in clinical trials [14,15]. However, this approach 
is expensive, time-consuming, and requires an extensive amount of clinical care resources 
[16–18]. An efficient method for comparing and assessing the performance of computer-
based clinical protocols prior to evaluation in the clinical setting would be valuable to 
address those concerns. 
Any computer-based clinical protocol must be evaluated extensively by healthcare 
practitioners before it can be utilized at the bedside. Flawed scientific evidence due to 
lacking or misinterpretation of results can lead to suboptimal development of computer-
based clinical protocols [19]. Unfortunately, investigating this issue in clinical trials is 
probably not be the best option because almost every clinical trial exposes patients to risk 
and some patients may be harmed during a trial. This makes it more challenging to compare 
alternative computer-based clinical protocols. By rethinking our approach to include 
preliminary evaluation of candidate computer-based clinical protocols, we can find a more 
effective in silico method that can help us identify computer-based clinical protocols 
worthy for clinical trials. 
1.2 Purpose of the Study 
The purpose of this study was to develop an informatics-based approach for comparing 
and evaluating computer-based clinical protocols. The framework proposed in this 
dissertation is an in silico method, with emphasis on computer simulations of physiological 





1.3.1 Aim 1 
The first aim of this study was to investigate the feasibility of developing an in silico 
method for identifying promising computer-based clinical protocols for clinical study. 
Research question 1.1: Can we develop an in silico method for comparing and 
evaluating alternative computer-based clinical protocols? 
Research question 1.2: How do we critique the clinical significance of the 
comparison? 
Aim 1 was addressed by developing an in silico method that could compare two 
computer-based clinical protocols using data linked to the use of one of the protocols. 
1.3.2 Aim 2 
The second aim of the study was to expand the in silico method to analyze and evaluate 
multiple computer-based clinical protocol candidates. 
Research question 2.1: How do we expand the favorability scoring algorithm to 
evaluate multiple computer-based clinical protocols? 
Research question 2.2: What are the advantages and disadvantages of the new in silico 
method? 
When addressing Aim 2, we designed a different approach to favorability scoring 
algorithm that could compare multiple computer-based clinical protocol candidates.  
1.3.3 Aim 3 
The third aim of the study was to design a method that can help healthcare practitioners 




Research question 3.1: What are the appropriate criteria for estimating the 
performance of computer-based clinical protocols?  
Research question 3.2: How do we measure and critique potential risks when 
comparing the outcome of the scoring models? 
Research question 3.3: How do we facilitate the decision-making process and present 
the results to the healthcare practitioners? 
To address Aim 3, we designed a method based on multiple-criteria decision analysis 
that can assign weights to alternative computer-based clinical protocols. 
1.4 Importance of the Study 
The in silico method plays an important role in the translation of research results to 
clinical practice. While the in silico method cannot replace actual clinical trials, many 
discoveries can be made in computer simulations before we invest in clinical evaluations. 
The performance of each computer-based clinical protocol and its expected outcome can 
be examined thoroughly for different clinical and patient scenarios. Therefore, healthcare 
practitioners can make a more informed decision about which computer-based clinical 
protocol is best suited for further evaluation. 
Our in silico method offers advantages in cost, time, and safety. The huge expenses 
related to a full-scale clinical trial can be reduced by conducting a pre-trial using in silico 
experiments. Since human subjects are not directly involved in the in silico method, clinical 
care resources are not required during this phase. Computer simulations using retrospective 
data derived from real patients clinically treated with a similar protocol allow healthcare 
practitioners to study how future patients may respond to the new treatment protocols. 




critical situations can be examined without posing any risk to actual patients. Finally, these 
evaluations can also enhance the development of computer-based clinical protocols 
because we can iteratively refine the protocol specifications and get an immediate 
estimation of clinical responses through the in silico method.  
1.5 Scope of the Study 
This dissertation study was limited to an investigation of in silico methods for 
comparing computer-based insulin infusion protocols. The computer-based insulin 
infusion protocols were specifically designed to treat patients with stress hyperglycemia 
using intravenous (IV) insulin infusion. The researcher did not systematically compare and 
contrast these computer-based insulin infusion protocols with other types of computer-
based clinical protocols, such as mechanical ventilator management or Coumadin dosing.  
1.6 Future Work 
This single study of computer-based insulin infusion protocol provides a richness of 
data and can lead to deeper understanding of the in silico method. The working hypotheses 
derived from this study can be tested in subsequent research. In the future, better simulation 
models can be developed using the in silico framework to determine which patient will 
benefit from the computer-based clinical protocol intervention. We could also better target 




2 REVIEW OF LITERATURE 
2.1 Computer-based Clinical Protocols 
Clinical guidelines and protocols can help healthcare practitioners to make decisions 
about the diagnosis, management, and treatment in specific areas of medicine [20–22]. 
They are the most effective method for disseminating evidence-based healthcare practices. 
Clinical guidelines are typically general statements about clinical recommendations and 
best practices based on the examination of current literature and expert opinions [20–22]. 
Clinical protocols are specialized, more detailed versions of the guidelines, often 
containing locally specific details or algorithms such as drug dosage schedules. For this 
research, we focused only on clinical protocols.  
Development methods for clinical guidelines and protocols can vary widely. 
Healthcare practitioners and researchers use a variety of heuristics or modeling techniques 
that may not reflect standardized clinician decision making [9,23–25]. Different methods 
may lead to different patient outcomes. 
Unaided healthcare practitioners and inconsistent use of clinical guidelines can affect 
their clinical care practice and health outcomes [26]. Compliance with guidelines and 
protocols among healthcare practitioners can vary widely even when they are based on 
reputable evidences [27–29].  As a result, patients can be harmed when clinicians do not 
comply with best evidence [30].  




protocols are implemented and disseminated [7,31]. Many of the challenges highlighted 
above can be resolved by implementing the clinical protocols in computers. Computer-
based clinical protocols can produce standardized clinical decisions while retaining the 
ability to adapt to contextual changes, thus personalizing patient care [7,31,32]. Computer-
based clinical protocols can offer a wider dissemination and effective use of clinical 
protocols while reducing variation in the treatment of patients [5–8]. Use of computer-
based clinical protocols has produced favorable clinical outcomes [2,5,6,33–35]. Studies 
have shown improved protocol adherence when healthcare practitioners use computer-
based clinical protocols [6,36,37]. Most importantly, computer-based clinical protocols 
have been reported to improve clinician performance, healthcare processes, and patient 
outcomes [4–6,38].  
2.2 Reasons for Comparing Computer-based Clinical Protocols 
It is anticipated that an increasing number of computer-based clinical protocols will 
be developed to meet the needs of healthcare [1,4,6,9,11,12,39]. However, extensive 
development of computer-based clinical protocols can also lead to variations in their 
implementation because they were developed in local institutions. The computer-based 
insulin infusion protocol for treating stress hyperglycemia is one such example [9–13]. 
Medical researchers who developed these computer-based clinical protocols used different 
heuristics, algorithms, expert opinions, and clinical evidence in their local implementation. 
Different methods, even though rigorous, can lead to different health outcomes. As 
expected, healthcare practitioners would prefer to use the most suitable computer-based 
clinical protocol that will have a positive impact in their clinical practice [40].  




engineers must transform clinical evidences, rules, and expert opinions into computable 
form so that healthcare practitioners can make appropriate clinical decisions with the aid 
of a computer [31]. The computer-based clinical protocol has to be tested extensively 
before it can be used in the clinical setting. Software testing ensures that the computer-
based clinical protocol meets the requirement, responds correctly to the inputs, and 
performs its functions accurately within an acceptable time. However, part of the 
knowledge engineering development lifecycle of a computer-based clinical protocol is to 
understand how the software can impact future patients. Therefore, software testing is 
inadequate in this respect because the test will only inform us whether the software 
components perform according to their specifications.  
While it is important to assess how the computer-based clinical protocol performs in 
an actual clinical environment, incorporating patient assessment in a clinical trial during 
the software testing phase poses a high risk for patients. It would be better to test the 
computer-based clinical protocol in a computer simulation and compare the performance 
with an existing protocol. Hence, an effective in silico method can help software developers 
and healthcare practitioners better understand the impact of the computer-based clinical 
protocol in a real-world setting.  
Since the computer-based clinical protocol is based on scientific data and expert 
opinion available at the time the protocol is adopted, the protocol must be constantly re-
evaluated and updated when new data and information become available [22]. Healthcare 
practitioners are usually involved in the adoption and evaluation of computer-based 
clinical protocols so that they can understand, accept, and use them effectively [26,31]. 




and patient benefits before and after the new evidence is incorporated into the computer-
based clinical protocol. 
2.3 Current Comparison Strategy for Computer-based Clinical Protocols 
Clinical evaluation for different strategies of care involving computer-based clinical 
protocols is challenging because of: (i) the complexity of clinical environment, (ii) the 
expense of clinical trials, (iii) the time necessary for these trials, (iv) the large consumption 
of clinical research and care resources during these trials, and (v) regulatory barriers [1,41]. 
A method of comparing different computer-based clinical protocols to determine those 
with sufficient merit to warrant evaluation in a clinical trial would be valuable to ease these 
challenges.   
It is in the interest of healthcare practitioners to evaluate the computer-based clinical 
protocols rigorously before they are implemented as a routine clinical intervention. Current 
evidence still suggests clinical trials as the best method to compare computer-based clinical 
protocols [14,15]. For example, Blaha et al. compared three insulin infusion protocols, 
including a computer-based insulin infusion protocol called enhanced model predictive 
control (eMPC) algorithm, in a randomized controlled trial [42]. However, as indicated 
above, this approach is expensive, utilizes large amount of clinical resources, and is time-
consuming [16–18]. 
Many comparisons typically involve a computer-based clinical protocol compared 
with a paper-based protocol or routine treatment management [9,12–14,42–46]. Morris et 
al. investigated two different versions of computer-based insulin infusion protocols used 
in clinical practices and compared their performance retrospectively [47]. Several 




systematic reviews [12,40,48,49]. These reviews yielded useful information, but 
unfortunately, are not adequate for healthcare practitioners to make a decision about 
selecting the best computer-based clinical protocol for further clinical study. The literature 
lacked in-depth analysis of the problem and contained limited critiquing of the protocols, 
mainly due to the heterogeneity of the case studies. 
Allart et al. outlined a software architecture to compare computer-based clinical 
protocols but did not address specific methods to evaluate them [50]. Lee et al. [51] 
described an in silico evaluation of insulin infusion protocols using virtual populations 
developed by Hovorka et al. [52]. However, the study did not use any real patients in the 
ICU or a fully developed computer-based insulin infusion protocol. It is plausible that these 
preliminary efforts could be extended to create a more effective strategy to compare and 
evaluate computer-based clinical protocols. 
2.4 Stressed-induced Hyperglycemia and Insulin Infusion  
Protocols for Blood Glucose Management  
in ICU Patients 
Critically ill patients often develop hyperglycemia (increased blood glucose above the 
normal range), insulin resistance, and glucose intolerance due to hypermetabolic stress 
[53]. Drugs such as steroids, beta blockers, diuretics, and niacin can cause clinically 
significant elevated blood glucose concentrations. Hyperglycemia is also seen as a 
response to stress due to elevated levels of cortisol and catecholamines. Hyperglycemia 
can also be seen in critically ill patients with no prior history of diabetes. 
Reports that intensive intravenous (IV) insulin therapy could decrease morbidity and 




of stress-induced hyperglycemia, and about the proper target for blood glucose [54,55]. As 
a result, many experts developed guidelines to manage blood glucose in these patients. 
Titration of IV insulin infusion is one of the most common clinical guidelines for critically 
ill patients. The goal is to maintain near-normal glycemic levels through continuous IV 
insulin infusion. However, this is not an easy task. Insulin sensitivity varies from person to 
person and at different time points in the same person. Human bodies have different 
physiologic responses that affect how insulin regulates blood glucose. Risk factors can 
include age, obesity, diet, genetics, infections, and medication. Because of the complexities 
in this process, unaided healthcare practitioner decisions about insulin dosing, or decisions 
using a general guideline, vary widely. A computer-based clinical protocol can help 
standardize the clinical decision-making process of adjusting appropriate IV insulin 
infusion for individual patients and increase compliance among healthcare practitioners 
[7,31,47]. 
2.5 Computer-based Insulin Infusion Protocols 
2.5.1 eProtocol-insulin 
Intermountain Healthcare implemented a detailed, adequately explicit, computer-
based protocol (eProtocol-insulin) for management of stress hyperglycemia in the intensive 
care unit (ICU) from 2004 to 2010 [37,47,56].  eProtocol-insulin is an open-loop, heuristic, 
rule-based system. It is an empiric protocol that recommends continuous IV insulin 
infusion rate, based on the difference between the most recent blood glucose and the blood 
glucose target, the rate of change of blood glucose, the current continuous IV insulin 
infusion rate, previous concentrated IV glucose doses (if any, for treatment of 




entered into eProtocol-insulin to get the next continuous IV insulin infusion rate 
recommendation. Bedside healthcare practitioners review each eProtocol-insulin 
recommendation before adjusting the continuous IV insulin infusion rate. If the healthcare 
practitioner declines the recommendation, the healthcare practitioner will set their 
preferred continuous IV insulin infusion rate according to their clinical judgment. Bedside 
healthcare practitioners accepted 95% of eProtocol-insulin recommendations [37,47,56].  
 This is an iterative method that produces intermediate outcome results (blood glucose 
value changes) that are either successful (fall within target range or move closer to the 
target range) or unsuccessful. The resulting clinical database with its sequence of 
successful and unsuccessful changes is unique because it is a robust reflection of the 
interaction between the eProtocol-insulin and ICU patients with stress hyperglycemia.  
This database provides a resource for comparison of eProtocol-insulin with other replicable 
methods for managing stress hyperglycemia. At any time point, the patient’s physiologic 
state can be estimated based on their response to the administered insulin. Comparison of 
the successful and unsuccessful response rates for eProtocol-insulin recommendations, and 
the probable responses produced by an alternative strategy, allows evaluation of their 
comparative clinical suitability. 
2.5.2 HWCIR Glucose Protocol 
The HWCIR Glucose Protocol is a derivation of eProtocol-insulin implemented as a 
.NET application in Intermountain Healthcare. This was done so that the application 
conformed to the enterprise standards for use at the bedside in Intermountain Healthcare. 
Several rules in the computer-based protocol were updated by healthcare practitioners to 




infusion when the blood glucose measurement falls below 60 mg/dL. 
2.5.3 Glucosafe 
Glucosafe is a complex, multi-organ physiologic model, decision support system for 
blood glucose management developed by University of Aalborg, Denmark [45,57,58]. 
Glucosafe recommended a continuous IV insulin infusion rate and an IV insulin bolus. The 
IV insulin bolus was only recommended when blood glucose exceeds 180 mg/dL. 
Glucosafe calculated insulin sensitivity based on blood glucose measurements, amount of 
insulin previously given, and various nutritional inputs. The model also considers insulin 
saturation effects and the glucose absorption rate as a function of carbohydrate content in 
the gastrointestinal tract (based on the rate and type of enteral feeding) [58]. Internally, 
Glucosafe had four penalty functions to optimize the amount of the continuous IV insulin 
infusion rate for every recommendation; blood glucose penalty, insulin penalty, caloric 
input penalty, and nutrition penalty [57,58]. Small-scale prospective studies were 
conducted in Europe to examine safety and performance issues [45,57]. 
2.5.4 Atlanta Medical Center Protocol 
The Atlanta Medical Center (AMC) protocol is a columnar insulin dosing chart 
developed by the Diabetes Special Interest Group (Georgia Hospital Association) in 
Georgia, USA to standardize the management of hyperglycemia [59]. The target blood 
glucose range was 80-110 mg/dL. A pilot study involving twenty patients was conducted 
at the Atlanta Medical Center in 2006 [59]. The average time to reach the target blood 
glucose range was 12.8 hours and hypoglycemia (below 60 mg/dL) was found in 0.9% of 




2.5.5 Thomas Jefferson Insulin Infusion Protocol 
The Thomas Jefferson Insulin Infusion Protocol (TJIIP) is a nurse-managed protocol 
for delivering continuous IV insulin infusion to hyperglycemic patients at the ICU; it was 
developed by Thomas Jefferson Hospital, Pennsylvania, USA [60]. The target blood 
glucose range was 100-140 mg/dL. Murphy et al. conducted a retrospective study on 108 
patients in a surgical cardiac care unit where their blood glucose were managed by TJIIP 
[60]. Median blood glucose was 154 mg/dL. Two hypoglycemic (less than 60 mg/dL) 
episodes were reported affecting two patients. However, it was not clear how many total 
blood glucose measurements were made. The article concluded that an intense use of 
insulin infusion protocol may not necessarily provide better glycemic control [60].  
2.5.6 Nice-Sugar Protocol 
The Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose 
Algorithm Regulation (NICE-SUGAR) study was a collaboration between the Australian 
and New Zealand Intensive Care Society Clinical Trials Group, the George Institute for 
International Health (University of Sydney), the Canadian Critical Care Trials Group, and 
the Vancouver Coastal Health Research Institute (University of British Columbia) on 
intensive glycemic control [61]. The NICE-SUGAR study investigators conducted a multi-
center randomized trial involving 6,104 patients admitted to the surgical and medical ICUs 
in 42 hospitals during the period from December 2004 to November 2008 [61]. The patients 
were randomly assigned to intensive glycemic control with a target blood glucose of 81-
108 mg/dL and conventional glycemic control with target blood glucose ≤ 180 mg/dL. The 
study found that the 90-day mortality rate for the intensive glycemic control group was 




Berghe et al. which had demonstrated a significantly lower ICU mortality in the intensive 
glycemic control arm [54]. Severe hypoglycemia (blood glucose ≤ 40 mg/dL) was also 
much higher in the intensive glycemic control arm of the NICE-SUGAR study (6.8% vs 
0.5%) [61].  
2.6 Computer Simulations for Comparing Computer-based  
Clinical Protocols 
Computer simulation continues to play an increasingly important role in medicine [62–
64]. For this study, we defined computer simulation as the act of imitating a real-world 
process or behavior over time. Computer simulations are often used in medical education, 
computer-based assessment, and physiological modeling research [65–68]. The advantage 
of using computer simulation includes the ability to analyze complex processes, examine 
critical issues, and mimic life-like situations using real patient data without impacting the 
health of patients [62]. Thus, medical researchers can investigate various scenarios of care 
including life-threatening situations without harming the actual patient [66].  
2.6.1 Computational Models 
Computer simulation in medicine often requires a computational model to represent a 
realistic situation, system, or process, and a set of virtual patients to act on the situation, 
system, or process [65,68–70]. For example, computational models for glucose regulation 
have been used to develop new insulin infusion algorithms [52,71,72]. Many of these 
simulation models and virtual patients were designed using mathematical models including 




Physiologically-based pharmacokinetic (PBPK) modeling is a mathematical modeling 
technique for predicting the absorption, distribution, metabolism, and excretion (ADME) 
of synthetic or natural chemical substances in humans and animals [67,68,75]. This 
approach has been demonstrated to be useful in identifying drug targets by applying the 
knowledge of pharmacodynamics interactions between drugs and biochemistry during the 
modeling of drug interaction [76]. Schaller et al. developed a deeper understanding of the 
insulin-glucose regulatory system by using this PBPK modeling approach [75].  
Another approach to mathematical modeling is through compartmental models where 
a collection of interconnected physiological compartments with specified inputs and 
outputs defined the system [70]. Hovorka et al. developed a complex system of five 
submodels (endogenous insulin secretion, insulin kinetics, enteral glucose absorption, 
insulin action, and glucose kinetics) for closed-loop glucose control [44,52]. Subsequently, 
Pielmeier adopted this model for the development of Glucosafe [58].  
Increasingly large amounts of clinical data are being delivered and stored in electronic 
format. This can lead to the development of more data-driven computational models in 
medicine. Parameter fitting models are a type of mathematical model where a function or 
complex equation is optimized to best fit to the data points. Some of the common parameter 
estimation techniques used are ordinary least squares, linear regression, and Bayesian 
inference [77,78]. Parameter fitting models have been used to study glucose-insulin 
regulation system [79–84]. 
2.6.2 Virtual Patients 
Virtual patients are reflection of actual patients engaged in healthcare during computer 




biochemical or physiological processes are simulated, (ii) responses based on the data from 
real patients from electronic health records (EHR), (iii) physical simulators such as 
mannequins, and (iv) simulated patients where the patient is recreated to engage in patient 
acting or role-play. Hovorka et al. coined the term “experimental in silico cloning” as the 
process of transforming clinical data from real patients into virtual patients [52]. Virtual 
patients derived from real patient data have been used to assist in the development and 
refinement of computer-based insulin infusion protocols [85,86].  
2.6.3 Using Computer Simulation for Computer-based  
Insulin Infusion Protocols Evaluation 
Preclinical trials using in silico methods have been studied to evaluate insulin infusion 
algorithms [72,87,88]. These trials involved a closed-loop strategy with virtual patients as 
subjects in the computer simulation [72,87,88]. However, these studies did not compare 
one insulin dosing algorithm with another computer-based clinical protocol.  
Wilinska et al. investigated two versions of a computer-based insulin infusion protocol 
(model predictive control (MPC)-based glucose control algorithm) in silico using 10 virtual 
patients [71]. These two versions were compared quantitatively using measures such as 
mean glucose, time in target, time to target, hypoglycemic episodes, and subjects with 
hypoglycemia [71]. Lee et al. investigated two insulin infusion protocols, SPRINT and 
NICE-SUGAR, using in silico method with a virtual patient model developed by Hovorka 
et al. [51,52]. Lee et al. ran a three-day simulation and the results were compared through 
the hyperglycemia and hypoglycemia index, blood glucose concentrations, insulin doses, 
intravenous glucose infusion rates, and glucose feed rates [51]. Lee et al. concluded that 




described a method of simulating blood glucose control and comparison of insulin 
protocols using 19 virtual patients derived from retrospective data [85]. However, the 
insulin protocols used by Lonergan et al. were not computer-based clinical protocols [85]. 
Similar studies by Wilinska et al. and Lee et al. suggested that their method also lacked a 
formal critiquing model for the insulin doses recommended by competing protocols and its 
clinical impact. Therefore, we were not able to adequately assess which protocols is better 
for future clinical trial evaluations. 
2.7 Decision-making and Multi-attribute Utility Theory 
Humans have limited ability to process information and make an informed decision 
within a given period of time. According to Halford et al., the number of variables that a 
person can mentally handle while solving a problem is four, at most five [89]. Healthcare 
practitioners are constantly making clinical decisions that have important implications to 
their patient outcomes [90]. However, most healthcare practitioners have difficulties 
handling large amounts of information given the constraints in a stressful clinical 
environment [90–93]. Poor clinical decisions can lead to adverse events, medical errors, 
and even death [94,95]. 
We often make decisions in our daily lives by considering simple criteria implicitly. 
Sometimes we are comfortable with the consequences of such decisions. However, when 
the stakes are high such as clinical decisions, we need to evaluate the problem and their 
criteria explicitly. This can lead to a more informed and better decision.   
We evaluate our decisions by weighing the options available to us. We try to make the 
best decision based on some standard of what is good or bad. Decision theory, as proposed 




evaluating decisions [96]. Methods supported by decision theory, such as the various 
methods used by psychologists to study the behavior of decision-making, or the study of 
voting rules by political scientists, can be applied to similar problems in other fields.  
To understand decision theory, let us first consider an example of choosing a car. The 
simplest case is when there is only one attribute to choose from, e.g., the look of the car. 
This is an example where the attribute being subjective to the decision maker. Suppose that 
you like the look of car A better than car B, and you like car B better than car C. Clearly, 
you should buy car A. In reality, there are additional attributes to consider. Attributes for 
choosing a car may be related to safety, engine performance, fuel economy, number of 
passengers, and price. In most cases, these attributes are explicit and well defined.  
Not all of the attributes of making a decision are created equal. Some attributes may 
be considered more important. We can make a more informed decision by weighing these 
attributes accordingly. A simple mechanism to express the value of an attribute is to use 
relative terms such as “better than”, “worse than”, or “equally good” [97]. They are used 
to compare two alternatives. However, this is not adequate when we have multiple 
candidates to consider. Another method of expressing the value of an attribute is to assign 
numerical values. The advantage of using numerical value is that we can evaluate the 
attributes mathematically.  
Multi-attribute utility theory is a structured methodology for evaluating and comparing 
alternatives when making an important decision [98]. A utility is defined as a measure of 
references or value satisfying a set of attributes. The multi-attribute utility theory is 
designed to find the most optimal choice by quantifying the desirability of each of these 




same numerical scale. This allows the comparison and evaluation of many diverse and 
disparate attributes such as cost, fuel economy, and safety. The end result is a rank ordered 
evaluation of alternatives that reflects the decision makers' preferences.  
Multi-attribute utility model allows decision makers to explore different ways of 
evaluating the alternatives by adjusting the weights assigned to the attributes. Since the 
criteria are known to the decision makers, the weights can be adjusted depending on the 
importance of the attributes to yield different results. The advantage of using a multi-
attribute utility model is that many points of view can be taken into consideration when 
making a group decision. The basis on which the alternatives are being compared and 
evaluated is made transparent to all parties involved. The multi-attribute utility model is 
most effective when the group of decision makers can come to a consensus on the attributes 
in the model.  
2.8 Social Choice Theory and Voting System 
Social choice theory is a study of collective decision processes and procedures [99]. 
Kenneth Arrow, one of the main proponents of this theory, developed a theoretical 
framework to analyze how we can combine individual opinions and preferences to form a 
collective decision [99]. Individual preferences can be modeled as a utility function. It is 
assumed that the individuals have a preference over all the alternatives in a particular order. 
The social welfare function will then aggregate these individual preferences in such a way 
as to maximize the social utility through the sum of individual utilities [99].  
In a democratic process, the voting mechanism is typically used to determine the 
decision for the group [99]. Essentially, voting facilitates social choice in a market place 




system has a set of rules which must be adhered to for a vote to be considered valid, and a 
method on how votes are being processed to get the final result [100]. Common voting 
systems are majority rule and proportional representation.  
The majority rule or plurality system is a voting system where the candidate who 
received more votes than any other candidates will win the election [100]. This may be 
referred as winner-take-all system. In this system, an underrepresented candidate does not 
have a chance to win a mandate. This may inevitably lead to only major players remaining 
on the table. Major players could also use gerrymandering tactics to influence or 
manipulate the electoral results.  
The proportional representation system is a voting system that allows candidates to be 
represented proportionally according to the vote received [100,101]. This will create more 
competition and give more voices to minor candidates. If there are only two candidates, 
the winner can simply be determined by using the majority voting system. However, when 
there are multiple candidates, a single winner may not be an ideal solution. Different voting 
systems may give different results.  
2.8.1 Single-winner Methods 
2.8.1.1 Single Voting 
In a single voting method, each voter is allowed to pick only one candidate at a time. 
The most common single voting method is called plurality or winner-takes-all. The 
candidate with the most votes wins, regardless of whether the candidate receives a majority 
of the votes. Runoff methods are used when the winner needs to be elected by the majority. 




2.8.1.2 Ranked Voting 
In a ranked voting system, each voter ranks the candidates in the order of their 
preferences. A score is given to each candidate based on their rank position [102]. This 
method is also known as the positional voting method [102]. Any distribution of points to 
the rank positions is valid as long as the value of the higher rank is worth more than the 
lower rank. The scores corresponding to the voters’ preferences are then aggregated for the 
final score. The candidate with the highest score is the winner. Although there is only one 
winner in this method, other candidates can still be considered as a substitute because of 
their rank positions.  
The standard positional voting method is called Borda count [102]. In a single-winner 
election with N candidates, the most preferred candidate will receive N points, followed by 
N-1 for the second preference, and so on. The point value can be defined as: 
 
 𝑣 = 𝑎 − (𝑟 − 1)𝑑 (2-1) 
 
where 
 v is the point value 
 a is the weighting of the first preference 
 r is the rank position 
 d is the common difference between the ranks 
 
The following (see Table 2.1) is an example where the weighting of the first 
preference, a, is equal to the number of candidates, N. 
Alternatively (see Table 2.2), the number of points each candidate receives can be the 
number of candidates ranked below them. The most preferred candidate will receive N – 1 




Table 2.1: An example of Borda count with five candidates 
Ranking Candidate Formula Points 
1st Candidate A N 5 
2nd Candidate B N-1 4 
3rd Candidate C N-2 3 
4th Candidate D N-3 2 
5th Candidate E N-4 1 
 
 
Table 2.2: An example of Borda count with N-i points 
Ranking Candidate Formula Points 
1st Candidate A N-1 4 
2nd Candidate B N-2 3 
3rd Candidate C N-3 2 
4th Candidate D N-4 1 











receiving zero points. Therefore, a candidate ranked in the ith place receives N-i points. 
2.8.2 Multiple-winner Methods 
2.8.2.1 Proportional Method 
The proportional method gives opportunity to all candidates to get some form of 
representation based on the votes they received [101]. In legislation, the most common 
proportional systems are based on party-list proportional representation. Voters vote for 
parties instead of individual candidates. Seats are then allocated according to the proportion 
of votes each party receives. There are different methods to determine the number of votes 
assigned to a seat, also known as quota. The methods of seat allocation can be grouped into 





3.1 Data Sources 
3.1.1 Data Collection 
The data source for the in silico comparison was the electronic medical record (EMR) 
database from patients admitted into LDS Hospital and Intermountain Medical Center in 
Salt Lake City, Utah. We extracted the data from Intermountain Healthcare’s HELP 
system, a health information system with an integrated clinical data repository. The HELP 
system stored chronological clinical data when eProtocol-insulin was used to manage 
patients with stress hyperglycemia. We included patients admitted into the ICU from 2004 
to 2010 who were at least 14 years old, had stress hyperglycemia, and were managed by a 
version of eProtocol-insulin whose blood glucose target range was 80-110 mg/dL [56]. 
3.1.2 Inclusion and Exclusion Criteria 
We included data for a group of patients who were supported by eProtocol-insulin in 
a single clinical encounter that contained more than five complete records of blood glucose 
and associated data. We extracted patient demographic records, blood glucose 
measurements, continuous IV insulin infusion rate, nutrition, IV propofol infusion rates 
                                                 
1 Figures 3.6, Equations 3.1 and 3.2 were reproduced and adapted with permission from Anthony F. 
Wong et al. An in silico method to identify computer-based protocols worthy of clinical study: An insulin 
infusion protocol use case. Journal of the American Medical Informatics Association (2016) 23 (2): 283-





(because propofol’s caloric value was used by Glucosafe), and presence and types of 
diabetes mellitus. Glucosafe uses quantified nutrition for computation of IV insulin 
infusion rate recommendation, whereas eProtocol-insulin does not. 
One of our computer-based insulin infusion protocol candidates, Glucosafe, requires 
more input data than eProtocol-insulin. To maximize the validity of results in our in silico 
comparison by using the same data for all candidates, we required a complete data set. We 
therefore eliminated a large number of records using the exclusion criteria decscribed 
below.  
We excluded patient cohorts who were supported by different versions of eProtocol-
insulin when they were transferred between hospitals. Glucosafe requires nutritional input 
for its IV insulin infusion rate recommendation. Therefore, we excluded patients that were 
neither given enteral nor total parenteral nutrition so that we have a complete data set. We 
excluded patients who had incomplete blood glucose measurements and insulin therapy 
data. We excluded patients whose records had missing information about clinician’s 
acceptance of eProtocol-insulin recommendations because we did not know their decisions 
at the bedside. We excluded patients who had missing eProtocol-insulin recommendations, 
or had five or less recorded observations because we needed this minimal number of 
sequential decisions for our evaluation algorithms. We excluded patients with recorded 
propofol infusion rates exceeding 200 mcg/kg/min. We believed this amount was simply 
too excessive and not reflective of the clinical decision made at the bedside. We excluded 
patients with two sequential measurements of blood glucose more than 12 hours apart, to 




3.2 Batch Comparison with Computer-based  
Clinical Protocol Candidates 
3.2.1 HWCIR Glucose Protocol 
The HWCIR Glucose Protocol program was modified to accept batched sequential 
data input from our curated data set. The output of the HWCIR Glucose Protocol program 
was the recommended continuous IV infusion rate.  
3.2.2 Glucosafe 
The Glucosafe program was modified to accept batched sequential data input. The 
output of Glucosafe was an insulin sensitivity estimate and recommendations for a 
continuous IV insulin infusion rate and an IV insulin bolus. 
3.2.3 Atlanta Medical Center Protocol 
We adopted this table-based protocol and developed our own computer-based version 
as Computer-based Insulin Infusion Protocol for Atlanta Medical Center Protocol (CIIP-
AMC). The following is a general outline of the rules of the protocol: 
 Start the insulin infusion using the drip rate for current blood glucose range. 
 Subsequent insulin infusion rate is determined by comparing the current blood 
glucose range and previous blood glucose range. 
 If the current blood glucose range is lower than the previous blood glucose range, 
stay in the same column of insulin dosing. 
 If the current blood glucose range is the same or higher than the previous blood 
glucose range, move one column to the right of insulin dosing. 




to determine the new insulin infusion rate. 
 If blood glucose is less than 80 mg/dL, move one column to the left. 
We did not implement the rules for rechecking blood glucose measurements and 
administration of concentrated glucose since they were not within the scope of this study 
evaluation. 
3.2.4 Thomas Jefferson Insulin Infusion Protocol 
We adopted this protocol and developed our own computer-based version as 
Computer-based Insulin Infusion Protocol for Thomas Jefferson Insulin Infusion Protocol 
(CIIP-TJIIP). The following is a general outline of the rules of the protocol: 
 The protocol limits the amount of insulin a patient can receive to a maximum of 20 
U/h. 
 The insulin infusion rate is determined via a table lookup using the current blood 
glucose and rate of change from the previous blood glucose level. 
We did not implement the rules for rechecking blood glucose measurements and 
administration of oral or concentrated glucose since they were not necessary for this study 
evaluation. 
3.2.5 NICE-SUGAR Protocol 
We adopted this protocol and developed our own computer-based version as 
Computer-based Insulin Infusion Protocol for Nice-Sugar Protocol (CIIP-NS). The 
following is a general outline of the rules of the protocol: 
 The calculation of the recommended IV insulin infusion rate depends on the 





 The amount of IV insulin infusion rate to recommend depends on whether the 
patient was previously on insulin. 
We did not implement the rules for rechecking blood glucose measurements and bolus 
administration of 50% glucose since they were not within the scope of this study. We also 
did not implement the action of giving the patient a stat dose of insulin as it was optional 
and at the discretion of the attending physician.  
3.3 In silico Framework 
3.3.1 Conceptual Design 
We developed a conceptual framework for our in silico method to compare and 
evaluate computer-based clinical protocols. The framework (see Figure 3.1) has three main 
components: (i) computer-based clinical protocols, (ii) data and physiological process 
simulation, and (iii) performance comparison and evaluation. The main purpose of the 
framework is to guide the design of a system for the comparison and evaluation of multiple 
computer-based clinical protocols. Our goal is to provide a framework for comparing any 
type of computer-based clinical protocols including those that are being used currently in 
the clinical setting or newly developed system. The framework was designed to support 
computer-based clinical protocols that were built on different computer platforms. This is 
important because many of these computer-based clinical protocols were developed by 
researchers based on the enterprise system used in their environment or familiarity with 





Figure 3.1: Conceptual framework for in silico comparison and evaluation of computer-
based clinical protocols 
3.3.2 Features 
The framework’s basic approach is to provide computer-based clinical protocols with 
access to specific physiological processes simulated with retrospective data derived from 
real patients. Figure 3.2 describes the simulation of patients responding to treatment when 
managed by computer-based clinical protocol candidates. A baseline assumption was that 
the model for the specific physiological process has to be developed with data from patients 
who were treated with a similar protocol. The specific physiological process depends on 
the type of computer-based clinical protocol being investigated. For example, we simulated 
the dynamics of blood glucose-insulin in order to compare computer-based insulin infusion 
protocols. Simulation was achieved by using real patient data to create a model to represent 
the dynamics of blood glucose-insulin.  













Figure 3.2: Physiological process simulation interacting with computer-based clinical 
protocols 
 
was recommended by a competing computer-based insulin infusion protocol. Results from 
the computer-based clinical protocols were collected by the performance comparison and 
evaluation module for further analysis. This module performed statistical and quantitative 
analysis. We anticipated healthcare practitioners and researchers would want to critique 
the performance of the computer-based clinical protocols before adopting them in their 
clinical setting. The module is customizable and will allow users to specify their own rules 
to critique the analysis.  
The in silico framework was designed to support computer-based clinical protocols 
implemented in different computer platforms (Figure 3.3). The performance comparison 
and evaluation module needed to be able to evaluate results from all these computer-based 





Figure 3.3: The comparison and evaluation module supporting multiple platforms 
3.4 Favorability Scoring 
There are many ways the performance of a computer-based clinical protocol could be 
evaluated. We could attempt to quantify the ability of computer-based clinical protocols to 
achieve their primary purpose. For example, we could compare the continuous IV insulin 
infusion rates recommended by competing computer-based insulin infusion protocols by 
critiquing the outcome of their subsequent blood glucose level. Alternatively, we could 
measure the rate of adverse events or undesirable outcomes such as estimating the number 
of hypoglycemic or hyperglycemic cases within a certain blood glucose range.  
Generally, we defined a favorability score as the performance measure of a computer-
based clinical protocol based on a set of predefined rules. We tended to focus our rules on 
clinical outcomes. For example, at low blood glucose (<80 mg/dL) and within the target 
range (80-110mg/dL), we preferred a lower continuous IV insulin infusion rate or no 
insulin at all to prevent hypoglycemia. At high blood glucose (>110 mg/dL), we preferred 




3.5 Methods for Aim 1 
The first aim of our research study was to investigate the feasibility of developing an 
in silico method for identifying promising computer-based clinical protocol. We identified 
computer-based insulin infusion protocols as the focus of our study because of our 
experience in managing stress hyperglycemia with eProtocol-insulin [37,47,56]. The focus 
for Aim 1 was to compare the performance of Glucosafe against eProtocol-insulin.  
We developed a proof of concept software based on the in silico framework to compare 
and evaluate our computer-based insulin infusion protocols. The following diagram 
described the major components of the proof of concept software and the flow of 
information between them (see Figure 3.4). The software comprised two major 
components: the patient module, and the performance comparison and evaluation module. 
The purpose of the patient module was to extract appropriate patient data from the 
EMR database and provide the patient data to Glucosafe (see Figure 3.4, step 1). Glucosafe 
batch processed these data by feeding the input data iteratively in chronological order (see 
Figure 3.4, step 2) to get the corresponding recommendations for continuous IV insulin 
infusion rates (see Figure 3.4, step 3 and Figure 3.5). 
The performance comparison and evaluation module processed the results after 
Glucosafe completed the batch processing (see Figure 3.4, step 4). During evaluation, 
Glucosafe may suggest an insulin bolus in addition to the recommendation of continuous 
IV insulin infusion rate. We converted the Glucosafe IV insulin bolus into its continuous 
IV insulin infusion rate equivalent (Insulinbolus_iv_equivalent), and added it to the continuous 
IV insulin infusion rate (InsulinGlucosafe_IV) to produce a total continuous IV infusion rate 




















𝑡𝑖𝑚𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡𝑤𝑜 𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 




 𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝐺𝑙𝑢𝑐𝑜𝑠𝑎𝑓𝑒_𝑓𝑖𝑛𝑎𝑙 = 𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝐺𝑙𝑢𝑐𝑜𝑠𝑎𝑓𝑒_𝑖𝑣 + 𝐼𝑛𝑠𝑢𝑙𝑖𝑛𝑏𝑜𝑙𝑢𝑠_𝑖𝑣_𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡 (3-2) 
 
eProtocol-insulin used blood glucose measurements and continuous IV insulin 
infusion rates at times ti and ti-1, to generate a new continuous IV insulin infusion rate 
recommendation at time ti (Figure 3.6). Glucosafe used blood glucose measurements and 
continuous IV insulin infusion rates at time ti and at all previous times to generate a new 
recommendation. For outcome evaluations, we used a moving window of width determined 
by two sequential times, ti and ti+1.  The blood glucose at time=ti+1 measured during the 
intervention by eProtocol-insulin was the outcome of the continuous IV insulin infusion 
rate recommended and given at time=ti (see Analysis of Glucose at time=ti+1 in Figure 3.6). 
We used this blood glucose measurement at time=ti+1 to compare the potential outcome of 
the insulin recommendation by Glucosafe with eProtocol-insulin. Comparison was 
performed iteratively over each of the accepted eProtocol-insulin recommendations. 
We defined the following blood glucose ranges at time=ti+1 for the analysis: 
 Low: < 80 mg/dL 
 On target: 80 – 110 mg/dL 
 High: > 110 mg/dL 





Figure 3.6: Temporal characteristics of eProtocol-insulin and Glucosafe. Times of data 
used for continuous IV insulin infusion rate recommendation and time of blood glucose 
used for assessment of the appropriateness of the continuous IV insulin infusion rate 
recommendation. 
 
if the continuous IV insulin infusion rate recommendation at time=ti was too high, 
appropriate, or too low.  The 80-110 mg/dL blood glucose target range was the target in 
the original eProtocol-insulin clinical application that provided the clinical data for our 
computer-based protocol comparison.  
We used the following evaluation strategy to identify which of the two continuous IV 
insulin infusion rate recommendations (from eProtocol-insulin or Glucosafe) was more 
favorable, because it was more likely to bring the blood glucose at time=ti+1 closer to the 
blood glucose target range of 80-110 mg/dL: 
 If the blood glucose measurement at time=ti+1 was low (<80 mg/dL), it is likely that 




of the two recommended continuous IV insulin infusion rates at time=ti was “more 
favorable” because it would likely have a lower risk of hypoglycemia. 
 If the blood glucose measurement at time=ti+1 was high (>110 mg/dL), it is likely 
that the continuous IV insulin infusion rate was lower than desired. The higher of 
the two recommended continuous IV insulin infusion rates at time=ti was “more 
favorable” because it may prevent hyperglycemia. 
 When blood glucose at time=ti+1 was within target (80-110 mg/dL), the lower of 
the two recommended continuous IV insulin infusion rates at time=ti was “more 
favorable” because it would likely have a lower risk of hypoglycemia. We used two 
methods to determine if the two recommended continuous IV insulin infusion rates 
were “equivalent”: if they were equal (analysis “a”) or if the higher infusion rate 
was within 10% of the lower infusion rate (analysis “b”) (Figure 3.6, “a” and “b”). 
10% was chosen arbitrary based on clinical heuristic. 
The following is an example of favorability scoring (see Figure 3.7) when the observed 
blood glucose level at time=ti+1 was deemed high (160 mg/dL) after the patient was given 
an insulin dose of 2.0 U/h as recommended by eProtocol-insulin at time=ti. If the 
continuous IV insulin infusion rate recommended by a computer-based insulin infusion 
protocol candidate at time=ti is lower than eProtocol-insulin, we think that the patient’s 
blood glucose level will drop at a slower rate compared to eProtocol-insulin. This is less 
desirable. However, if the continuous IV insulin infusion rate recommended by the 
computer-based insulin infusion protocol candidate is higher, we think this could bring the 
blood glucose level down to the target range sooner. We consider this to be more favorable.  





Figure 3.7: An example of favorability scoring when the observed blood glucose at 
time=ti+1 is high. 
 
 
Figure 3.8: An example of favorability scoring when the observed blood glucose at 






blood glucose level at time=ti+1 was in the target range (90 mg/dL) after the patient was 
given a continuous IV insulin infusion rate of 1.0 U/h as recommended by eProtocol-
insulin at time=ti. If the recommended continuous IV insulin infusion rate by a computer-
based insulin infusion protocol candidate is higher than eProtocol-insulin, we thought this 
would cause the blood glucose level to drop even further. We preferred a lower insulin 
dose at this point in order to prevent a case of hypoglycemia. We defined continuous IV 
insulin rates as clinically equivalent when they are within 10% of each other (10% rule; (b) 
in Figure 3.6) in some analyses. If we applied the 10% rule, we allow the recommended 
continuous IV insulin infusion rate by a computer-based insulin infusion protocol candidate 
(Glucosafe) to fall within the 10% of the recommendation from eProtocol-insulin in order 
to determine their favorability as equivalent to eProtocol-insulin. 
3.5.1 Performance Comparison and Evaluation 
We analyzed the results using two different methods: statistics and favorability 
scoring. First, we analyzed the recommended continuous IV insulin infusion rates at time=ti 
(a continuous variable) from eProtocol-insulin and Glucosafe by performing a simple 
descriptive statistics (mean and median). We also measure the statistical dispersion of the 
distribution by measuring the standard deviation and interquartile range (IQR).   
As for favorability scoring, a point is given to the computer-based insulin infusion 
protocol (eProtocol-insulin or Glucosafe) for every iteration of the data set that has a more 
favorable recommended continuous IV insulin infusion rate. The results were then 





3.5.2 Statistical Analysis 
3.5.2.1 One Sample Z-test for Proportion (for Distributions  
of IV Insulin Infusion Rates) 
We conducted one-sample z-tests for proportions to assess the proportion of eProtocol-
insulin and Glucosafe pairs of recommended IV continuous insulin infusion rates that were 
not equivalent at time=ti+1. We assessed if the more favorable fractions for eProtocol-
insulin or for Glucosafe (categorical variables) at time=ti+1 were significantly different 
from 0.5 expected from chance alone. We evaluated more favorable fractions for three 
categories of blood glucose measurement at time=ti+1: low (< 80 mg/dL), on target (80-110 
mg/dL with equivalence analyses (a) and (b)), and high (>110 mg/dL). 
3.5.2.2 Wilcoxon Signed Rank Test (for favorability scores) 
We used the Wilcoxon signed rank test to compare the distributions of recommended 
continuous IV insulin infusion rates at time=ti. 
3.6 Methods for Aim 2 
The second aim of our study was to expand the in silico method to analyze and evaluate 
multiple computer-based clinical protocol candidates. The methods as described in Aim 1 
were limited to analyzing two computer-based insulin infusion protocols at a time. The 
methods were also limited to comparison with eProtocol-insulin because eProtocol-insulin 
became the source of data for the analysis.  When addressing Aim 2, we used a ranking 
strategy as a favorability scoring algorithm to compare multiple candidates of computer-
based insulin infusion protocols. 







 HWCIR Glucose Protocol 
 Atlanta Medical Center Protocol 
 Thomas Jefferson Insulin Infusion Protocol 
 NICE-SUGAR Protocol 
We developed the ranking strategy for favorability scoring based on a ranked voting 
system using Borda count. We preferred this strategy as opposed to the single voting 
strategy because single voting strategies aggregate all but the “winner” into a single 
“losing” category and we wanted a way to compare relative merits of the computer-based 
insulin infusion protocols. This is useful because organizational or other factors may 
influence healthcare practitioners to decide on a different computer-based insulin infusion 
protocol other than the winner of our evaluation. We used a moving window of two 
sequential times, ti and ti+1, for our outcome evaluations. Each iteration of the candidates’ 
recommended continuous IV insulin infusion rate was given a score by evaluating their 
rank in terms of favorability. We defined favorability as those more likely to bring the 
blood glucose at time = ti+1 to the blood glucose target range of 80-110 mg/dL. The strategy 
required us to retrospectively compare recommended continuous IV insulin infusion rate 
at time=ti relative to the subsequent blood glucose measurement at time=ti+1. 
The following describes how recommended continuous IV insulin infusion rates were 
ranked according to their favorability: 




continuous IV insulin infusion rate was higher than desired. A lower continuous IV 
insulin infusion rates at time = ti recommended by the candidates was deemed 
“more favorable” because it would likely have the lower danger of hypoglycemia. 
 If the blood glucose measurement at time=ti+1 was high (> 110 mg/dL), the 
continuous IV insulin infusion rate was lower than desired and a higher 
recommended continuous IV insulin infusion rates at time = ti was “more 
favorable.” 
 When blood glucose at time = ti+1 was within target (80-110 mg/dL), the lower 
recommended continuous IV insulin infusion rates at time = ti was “more 
favorable” because it would likely have the lower danger of hypoglycemia. 
We used a standard competition ranking strategy to assign the rankings. The computer-
based insulin infusion protocol candidate that was considered more favorable will receive 
a higher rank. Candidates that recommended exactly the same amount of continuous IV 
insulin infusion rates will receive the same ranking number. For example, if A ranks ahead 
of B and C (compare equal), followed by D, then A gets ranking number 1 (first), B and C 
get ranking number 2 (joint second), and D gets ranking number 4 (fourth). Finally, we 
converted the ranking into a score using the Borda count formula (see Equation (2-1)) with 
 








 𝑆𝑐𝑜𝑟𝑒𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒𝑠 − 𝑅𝑎𝑛𝑘𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒  (3-3) 
3.7 Methods for Aim 3 
The third aim of our study was to design a method of aiding our healthcare 
practitioners to make the right decision when choosing a computer-based clinical protocol 
for an upcoming clinical trial. The key to this design was to develop a multiple-criteria 
decision analysis with input from healthcare practitioners. 




 HWCIR Glucose Protocol 
 Atlanta Medical Center Protocol 
 Thomas Jefferson Insulin Infusion Protocol 
 NICE-SUGAR Protocol 
3.7.1 Estimating the Subsequent Blood Glucose Level 
There was a limitation with the methods described in Methods for Aim 1 and Methods 
for Aim 2. We operated under the assumption that the subsequent blood glucose (at 
time=ti+1) remain the same during the analysis for those methods mentioned above. We 
were not able to determine if the amount of continuous IV insulin infusion rate 
recommended by the computer-based insulin infusion protocol candidates was considered 




hypoglycemia or hyperglycemia depending on the amount of continuous IV insulin 
infusion rate. We can improve the favorability scoring by predicting the subsequent blood 
glucose level when a different continuous IV insulin infusion rate is given. 
In previous studies, the prediction of subsequent blood glucose level was calculated 
by using insulin sensitivity profiles [85,86]. These insulin sensitivity profiles, a 
dimensionless factor, were estimated from parameters (e.g., nutrition, insulin dose, blood 
glucose measurement) obtained from patients in a clinical trial. The insulin sensitivity 
estimate varies between blood glucose measurements. The relationship between insulin 
doses and change in blood glucose was not clear either (see Figure 3.9).  
Many complex mathematical models have been theorized to describe the dynamics of 
blood glucose and insulin including ordinary differential equations (ODEs), partial 
differential equations (PDEs), and stochastic models [73,83,84]. We chose a simple linear 
model to describe the relationship between insulin and blood glucose in our first prototype.   
In this study, we used the eProtocol-insulin’s observed rate of change of blood glucose 
per unit of insulin at time=ti to estimate the subsequent blood glucose level for other 
computer-based infusion protocol candidates at time=ti+1. First, we compute the rate of 





𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡+1 −  𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡
(𝑡𝑖𝑚𝑒 = 𝑡𝑖+1) − (𝑡𝑖𝑚𝑒 = 𝑡𝑖)
 (3-4) 
 



















We assumed the rate of change for blood glucose per unit of insulin dose remains the 
same for this patient when treated with another computer-based insulin infusion protocol 
candidate. 
 
 𝑑𝐵𝐺_𝐼𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒 = 𝑑𝐵𝐺_𝐼𝑒𝑃𝑟𝑜𝑡𝑜𝑐𝑜𝑙−𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (3-6) 
 
Then, we calculated the new rate of change based on a new dose recommendation by 
the computer-based insulin infusion protocol candidate. Finally, the blood glucose level at 
time=ti+1 was estimated to be: 
 𝑒𝑠𝑡_𝐵𝐺𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒
= 𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡 + (𝑑𝐵𝐺_𝐼𝑒𝑃𝑟𝑜𝑡𝑜𝑐𝑜𝑙−𝑖𝑛𝑠𝑢𝑙𝑖𝑛
× 𝑖𝑛𝑠𝑢𝑙𝑖𝑛𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒 × 𝛿𝑡𝑖) 
(3-7) 
 
In the following example (see Figure 3.10), the patient’s blood glucose had reduced 
from 180 mg/dL to 120 mg/dL after she was given 2.0 U/h of continuous IV insulin 
infusion, as observed in the eProtocol-insulin clinical trial. A computer-based insulin 
infusion protocol candidate recommended a higher insulin dose. The favorability scoring 
in Methods of Aim 1 would have judged the candidate more favorably because higher 





Figure 3.10: An example of estimating the subsequent blood glucose to determine the 
favorability 
 
the recommended continuous IV insulin infusion rate is too high for the same time period. 
The descent of blood glucose level may be too steep. Again, if we assume that healthcare 
practitioners will only return at time=ti+1 to check on their patient, the blood glucose level 
now may be too low or possibly hypoglycemic. 
We estimated the subsequent blood glucose level at time=ti+1 by calculating the rate 
of change of blood glucose in that patient data due to insulin. To illustrate this, we created 
a simple input data for estimating the subsequent blood glucose level in Table 3.1. 
First, we calculated the rate of change of blood glucose during the time window of ti 






Table 3.1: An example input data for estimating the subsequent blood glucose level for a 
computer-based insulin infusion protocol candidate 











Blood glucose (mg/dL) 220 115 
Continuous IV insulin infusion rate given (U/h) 1.6  






e Continuous IV insulin infusion rate 







𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡+1 −  𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡




























If we assume the computer-based insulin infusion protocol candidate recommended is 
2.2 U/h at time=t1, the estimated blood glucose level at time=t2 for the computer-based 
insulin infusion protocol candidate according to Equation (3-7) would be:  
 
𝑒𝑠𝑡𝐵𝐺𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒 = 𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒𝑡 + (𝑑𝐵𝐺𝐼𝑒𝑃𝑟𝑜𝑡𝑜𝑐𝑜𝑙−𝑖𝑛𝑠𝑢𝑙𝑖𝑛 × 𝑖𝑛𝑠𝑢𝑙𝑖𝑛𝑐𝑎𝑛𝑑𝑖𝑑𝑎𝑡𝑒 × 𝛿𝑡𝑖) 
= 220 + (−43.75 × 2.2 × 1.5) 
= 𝟕𝟔 𝒎𝒈/𝒅𝑳 
 
The patient is now fast approaching the hypoglycemic range (see Figure 3.11). 
Although this result may have been more favorable using the previous favorability 
analysis (higher insulin infusion rate was preferred), the estimate of subsequent blood 
glucose demonstrated that the observation may be fast approaching hypoglycemia. This is 
not desirable.  
3.7.2 Multiple Criteria Decision Analysis 
We developed several criteria to help healthcare practitioners decide which of the 
computer-based insulin infusion protocol candidates is suitable for clinical trial. The 
criteria were also designed to probe the behavior and performance of the computer-based 
insulin infusion protocol candidates.  
3.7.2.1 Ranked Favorability Scoring 
The objective of the ranked favorability scoring was to analyze the perceived 
favorability for each computer-based insulin infusion candidate by comparing the 





Figure 3.11: The estimated blood glucose at time=t2 due to candidate’s recommended 
insulin 
 
to the subsequent blood glucose measurement at time=ti+1. We used the ranked favorability 
scoring as described in Methods for Aim 2. We selected the total aggregate score for the 
computer-based insulin infusion protocol candidates as our scoring criterion in this 
decision analysis. 
3.7.2.2 Estimation of Hypoglycemia Rate 
The objective of this criterion was to anticipate the risk of hypoglycemia when 
intervening with the computer-based insulin infusion protocol candidate. We used this 






3.7.2.3 Estimation of Hyperglycemia Rate 
The objective of this criterion was to anticipate the risk of hyperglycemia when 
intervening with the computer-based insulin infusion protocol candidate. We used this 
method to identify individual cases where the estimated subsequent blood glucose > 180 
mg/dL. 
3.7.2.4 Estimation of Cases Within the Target Range 
The objective of this criterion was to determine the percentage of cases where the 
blood glucose will fall within the target range when intervening with the computer-based 
insulin infusion protocol candidate. We used this method to identify individual cases where 
the estimated subsequent blood glucose is within the target range (80-110 mg/dL). 
3.7.2.5 Mean of Recommended Continuous IV Insulin Infusion Rates 
The objective of this criterion was to measure the central tendency of the output from 
computer-based insulin infusion protocol candidates. We stratified the output into different 
blood glucose range categories and calculated the mean of the recommended continuous 
IV insulin infusion rates at time=ti for each candidate. 
3.7.2.6 Median of Recommended Continuous IV Insulin Infusion Rates 
The objective of this criterion was to provide an alternative measure for the central 
tendency of the output from computer-based insulin infusion protocol candidates. The 
advantage of median is that it will not be influenced by outliers (extremely large or small 
values). The measure of median is one of the ways of summarizing the typical values 




Similarly, we stratified the output into different blood glucose range categories and 
calculated the median of the recommended continuous IV insulin infusion rates at time=ti 
for each candidate. 
3.7.2.7 Distributed Favorability Scoring 
The objective of this criterion was to measure the variability of the candidates in terms 
of how well the computer-based insulin infusion protocol candidate maintains the patient 
within the target range. Scores were assigned to each estimated subsequent blood glucose 
(method for subsequent blood glucose estimation was discussed in section 3.7.1) for all 
computer-based insulin infusion protocol candidates. The candidate received a higher score 
if their estimated blood glucose was closer to the blood glucose target range. We defined 
the our distributed favorability scoring as seen in Figure 3.12. 
3.7.3 Aggregating Decision Scores 
The scores from all the criteria were totaled before presenting the final results to the 
healthcare practitioners. We calculated these scores based on ranked voting and Borda 
count method. We assigned ranks to each of the candidates for every criterion to get a 
uniform score during aggregation. Weights were then assigned to the criteria with input 
from healthcare practitioners. These weights represent the strength and importance of the 
criteria, from the perspective of the local clinical experts, when judging the performance 
of the computer-based clinical protocol. In some environments, for example, efficiency in 
reaching protocol targets may be the most important concern, whereas in other 
environments, the over-riding concern might be avoiding a specific adverse event (like 





Figure 3.12: Assignment of scores for distributed favorability scoring 
 
winner proportional methods as described in the social choice theory (section 2.8). We 
preferred the multiple-winner methods as oppose to single-winner methods because we 
believe each of the computer-based clinical protocols has tangible value to healthcare 
practitioners. This method allowed us to judge each of the computer-based clinical protocol 








4 RESULTS AND DISCUSSIONS2 
4.1 Aim 1 
4.1.1 Results for Aim 1 
We found 2,560 patients managed by eProtocol-insulin at the LDS Hospital and 
Intermountain Medical Center from 2004 to 2010. These patients were managed by five 
different versions of eProtocol-insulin (see Table 4.1). We found 38 patients enrolled in 
two versions of eProtocol-insulin. We decided to exclude patients with multiple versions 
of eProtocol-insulin. We focused our patient data on eProtocol-insulin version “DA 95(80-
110)Jjrt4cMR” because the target range is 80 to 110 mg/dL and has the most patients in 
the database. 
We extracted deidentified patient demographic records, blood glucose measurements, 
continuous IV insulin infusion rate, nutrition, IV propofol infusion rates, presence and 
types of diabetes mellitus, and nutritional data (enteral and total parenteral nutrition). 
Glucosafe requires more data input than eProtocol-insulin to make a continuous IV insulin 
infusion rate recommendation. The input data include IV propofol infusion rate, types of 
diabetes mellitus, and nutritional data. We found several data fields with incomplete data 
(see Table 4.2). They may be incomplete due to missing data, patients who were not 
                                                 
2 Figures 4.1, Tables 4.3, 4.4, 4.6, and 4.7 were reproduced and adapted with permission from 
Anthony F. Wong et al. An in silico method to identify computer-based protocols worthy of clinical study: 
An insulin infusion protocol use case. Journal of the American Medical Informatics Association (2016) 23 





Table 4.1: Number of patients in different versions of eProtocol-insulin 
eProtocol-insulin 
version name 
Number of patients in 
each eProtocol-insulin 
Number of patients 
excluding those with 
multiple enrolment 
DA 115(90-140)Jjrt4cMR 449 440 
DA 115(90-140)JjrtEq4bBSA 29 21 
DA 95(80-110)Jjrt4cMR 1,375 1,351 
DA 95(80-110)JjrtEq4bBSA 486 466 













Table 4.2: Completeness of patient data 
Patient data field 
Number of patients having 
the required data 
% Complete 
Age 2,560 100.0 
Weight 2,560 100.0 
Height 2,558 99.9 
Gender 2,560 100.0 
Has Diabetes Mellitus Code 1,027 40.2 
Enteral nutrition 1,541 60.2 
Blood glucose 2,560 100.0 
Continuous IV insulin infusion 
rate 
2,560 100.0 
Total parenteral nutrition (TPN) 380 14.8 
Enteral OR TPN 1,635 63.9 










diagnosed with any types of diabetes, or patients not given any of the enteral nutrition or 
TPN during their hospitalization. The actual reasons were not documented. 
Our goal was to use data associated with eProtocol-insulin continuous IV insulin 
infusion rate recommendations accepted by the bedside healthcare practitioners. We 
examined 118,377 eProtocol-insulin recommendations from 2,560 patients. While the 
target for data acquisition interval was two hours, the realities of delivering care in a clinical 
setting results in some timing variability (median=2.05 hours, standard deviation=0.81 
hour, mean=2.10 hours). We eliminated the incomplete data using the exclusion criteria 
described in the methods section (see Figure 4.1). We excluded 2,152 patients initially 
using the exclusion criteria, leaving 408 patients with 20,770 eProtocol-insulin 
recommendations. We removed the 3.7% of 20,770 eProtocol-insulin recommendations 
rejected by bedside healthcare practitioners and used only eProtocol-insulin 
recommendations accepted by bedside healthcare practitioners. This was done to ensure 
that the data set from the observations reflected the decisions made by healthcare 
practitioners at the bedside. We also removed another 1,021 records because blood glucose 
at time= ti+1 was not available or because the records followed an eProtocol-insulin 
recommendation rejected by the bedside healthcare practitioners. The final result was a 
sample data set containing 408 patients with 18,984 eProtocol-insulin recommendations 
and associated data. 
We analyzed our study sample of 408 patients and found 11 patients with type 1 
diabetes and 113 patients with type 2 diabetes. There were 241 males and 167 females in 
the study sample. The statistical description of the patients can be found in Table 4.3. 











Table 4.3: Statistical description of patients 
 Min Max Mean 
Standard 
Deviation 
Age (years) 14 95 49.5 20.3 
Weight (kg) 39.5 275.8 86.3 26.0 
Height (cm) 139.7 208.3 173.1 10.3 
 
 
in the study sample (see Table 4.4). The majority of the patients in the data sample suffered 
from trauma or sepsis infections (216 of 408 patients). 
We analyzed the results of the recommended continuous IV insulin infusion rates from 
eProtocol-insulin and Glucosafe when blood glucose is at time=ti. They were clinically 
similar (see Table 4.5 and Figure 4.2) although statistically significantly different 
(Wilcoxon signed rank test p=0.01). 
We plotted the distributions of the recommended continuous IV insulin infusion rates 
by eProtocol-insulin and Glucosafe (see Figure 4.2). eProtocol-insulin appeared to 
recommend insulin infusion rates between 2 to 5 U/h more frequently than Glucosafe. 
Glucosafe recommended insulin infusion rates between 6 to 9 U/h slightly more frequently 
than eProtocol-insulin. 
When we stratified the time=ti continuous IV insulin infusion rates by the three blood 




Table 4.4: Primary discharge diagnostic categories for eProtocol-insulin patients in the 
data sample 








Gall Bladder/Pancreas 5 
Malignancy 20 
Diabetes Mellitus 2 
Other Endocrine 1 
Renal 7 
Central Nervous System 2 







(Table 4.4: Continued) 
























Table 4.5: Statistical results of recommended continuous IV insulin infusion rates 
between eProtocol-insulin and Glucosafe 
 eProtocol-insulin Glucosafe 
Mean (U/h) 3.9 4.0 
Median (U/h) 3.3 3.5 
Standard deviation (U/h) 2.7 3.1 
Minimum (U/h) 0 0 




Figure 4.2: Distributions of recommended continuous IV insulin infusion rate by 







recommended time=ti IV continuous insulin infusion rates from eProtocol-insulin and from 
Glucosafe were not only statistically significantly different (Wilcoxon signed rank test, 
p<0.001), but also appeared clinically different (see Figure 4.3). 
Finally, we analyzed the favorability using the evaluation strategy as outlined in the 
methods section. In analysis [a] (see Table 4.6), the continuous IV insulin infusion rate 
recommendations of eProtocol-insulin and Glucosafe are equivalent only when they are 
equal. In analysis [b] (see Table 4.6), the continuous IV insulin infusion rate 
recommendations of eProtocol-insulin and Glucosafe are equivalent only when they are 
within 10% of the lower continuous IV insulin infusion rate recommendation. Glucosafe’s 
continuous IV insulin infusion rate recommendations were found to be more favorable than 
those of eProtocol-insulin in all three time=ti+1 blood glucose categories. Analysis [b] has 
a higher portion of continuous IV insulin infusion rate recommendations that were 
considered to be equivalent compared to analysis [a] (14% vs 5%).  
We further analyzed the continuous IV insulin infusion rate recommendations from 
eProtocol-insulin and Glucosafe by studying their statistical dispersion. We reported the 
medians and interquartile range (IQR) of the continuous IV insulin infusion rate 
recommendations because their distributions appeared skewed. We reported the mean and 
standard deviation of the pairwise differences (Glucosafe minus eProtocol-insulin) because 
their differences appeared normally distributed.  
For blood glucose < 80 mg/dL, Glucosafe recommended lower median rates of 
continuous IV insulin infusion (1.5 U/h) than eProtocol-insulin (3.4 U/h) and Glucosafe’s 
recommendations were more favorable 80% of the time (see Table 4.6 and Table 4.7). This 





Figure 4.3: Distributions of recommended continuous IV insulin infusion rate by 




Table 4.6: Counts of more favorable continuous IV insulin infusion rate 
recommendations at time=ti from eProtocol-insulin or Glucosafe, based on three blood 


















< 80  273 (15%) 1470 (80%) 102 (5%) 
80-110 
[a] (continuous IV 
insulin infusion rate 
recommendations 
exactly equal) 
2919 (31%) 5984 (64%) 453 (5%) 
[b] (continuous IV 
insulin infusion rate 
recommendations ± 
10% of the lower 
infusion rate) 
2483 (26%) 5573 (60%) 1300 (14%) 




Table 4.7: Continuous IV insulin infusion rate recommendations and difference in 









Continuous IV insulin infusion 






















Low (< 80 mg/dL) 1845 3.4 (3.5) 1.5 (3.2) -1.8 (2.4) 
On target (80 – 110 mg/dL) 9356 3.3 (3.2) 2.8 (3.6) -0.8 (2.2) 
High (> 110 mg/dL) 7783 3.3 (2.8) 5.4 (4.7) 1.7 (2.9) 




low blood glucose range. For blood glucose > 110 mg/dL, Glucosafe recommended higher 
median rates of continuous IV insulin infusion (5.4 U/h) than eProtocol-insulin (3.3 U/h) 
and Glucosafe recommendations were more favorable 70% of the time (see Table 4.6 and 
Table 4.7). This was consistent with the notion that higher continuous IV insulin infusion 
rate is preferable at higher blood glucose range. For blood glucose within the target range 
(80-110 mg/dL), Glucosafe recommended lower median rates of continuous IV insulin 
infusion (2.8 U/h) than eProtocol-insulin (3.3 U/h) and Glucosafe recommendations were 
more favorable 64% of the time for analysis (a) and 60% of the time for analysis (b) (see 
Table 4.6 and Table 4.7).  Further, the proportion of continuous IV insulin infusion rate 
recommendations deemed more favorable (see Table 4.6) was significantly different from 
0.5 for both Glucosafe and eProtocol-insulin in each of the three blood glucose categories 
(one-sample z-test, p<0.001).   
4.1.2 Discussion for Aim 1 
We have successfully performed an in silico comparison and evaluation of two 
computer-based insulin infusion protocols, eProtocol-insulin and Glucosafe, using a robust 
EMR database generated from previous use of eProtocol-insulin at the bedside. eProtocol-
insulin has been proven to be effective in managing stress hyperglycemia in the ICU. This 
dependable clinician decision-making method allowed us to use the clinical EMR data to 
rigorously evaluate Glucosafe and assess its worthiness for expensive and resource 
consumptive evaluation in a clinical trial.  
The recommended continuous IV insulin infusion rates at time=ti for eProtocol-insulin 
and Glucosafe were found to be statistically significantly different even though they 




(low, on target, high) at time=ti+1, the continuous IV insulin infusion rate recommendations 
at time=ti were both statistically significantly different and the difference appeared 
clinically important (see Table 4.6 and Table 4.7). Glucosafe produced considerably more 
favorable continuous IV insulin infusion rate recommendations than eProtocol-insulin (see 
Table 4.6). In the low range, Glucosafe consistently recommended lower continuous IV 
insulin infusion rate than eProtocol-insulin and could potentially reduce the hypoglycemia 
rates. In the high range, Glucosafe recommended higher continuous IV insulin infusion 
rate more frequently than eProtocol-insulin. In other words, this could potentially lower 
the blood glucose level to the desired target range faster than eProtocol-insulin. These 
results suggested Glucosafe was the preferable computer-based insulin infusion protocol.  
The result in analysis [b], where we allowed the recommended continuous IV insulin 
infusion rate to stay within 10% of the other candidate in order to be considered equivalent, 
showed a significantly higher percentage compared to analysis [a]. We introduced this 
analysis as an experiment to see whether an interval band will affect the favorability 
scoring. The result suggested that, while the number of equivalents was higher in the 10% 
interval band, it did not affect the favorability scoring. Glucosafe still scored significantly 
better than eProtocol-insulin in this blood glucose category. 
The internal implementation of the computer-based insulin infusion protocols has 
played an important role in this outcome. Glucosafe was designed using a comprehensive 
physiologic algorithm that includes detailed nutritional information and effects of insulin 
sensitivity [57,58]. On the other hand, eProtocol-insulin was developed through years of 
protocol management in hypermetabolic stress. The insulin protocol used heuristic models 




[56]. We believed the detailed enteral and total parenteral nutritional information included 
in Glucosafe was one of the key factors why it had been able to recommend more favorable 
continuous IV insulin infusion rate compared to eProtocol-insulin.  
There were several limitations in the Methods for Aim 1. The pairwise comparative 
technique can only evaluate two computer-based insulin infusion protocols concurrently. 
In order to evaluate more than two computer-based insulin infusion protocols, we will need 
to compare them pairwise, repeatedly, for all combinations. This was certainly not the most 
efficient way to compare multiple computer-based insulin infusion protocols. Furthermore, 
it was not easy to judge their relative performance using this method.  
The version of Glucosafe in this evaluation only used the minimum amount of 
information that was required as we wanted to limit the scope of work. We think Glucosafe 
might perform even better if more clinical data were made available because the internal 
algorithm of Glucosafe allows more detailed computation.  
While we only compared two computer-based insulin infusion protocols for the ICU, 
the in silico method we developed seems generally applicable to other insulin infusion 
protocols. We demonstrated that the in silico method was an effective method to evaluate 
a computer-based insulin protocol candidate before committing the resources to conduct a 
clinical trial.  
4.2 Aim 2 
4.2.1 Results for Aim 2 
The second aim of our study was to expand the in silico method to evaluate multiple 
computer-based clinical protocol candidates. We found several limitations to the methods 




Previous methods required us to compare the candidates multiple times since only two 
candidates can be compared each time. To address this limitation, we used ranking strategy 
to rank and compare multiple computer-based clinical protocol candidates. In this study, 
we compared and analyzed six computer-based insulin infusion protocols: 
 eProtocol-insulin 
 Glucosafe 
 HWCIR Glucose Protocol 
 Atlanta Medical Center Protocol (CIIP-AMC) 
 Thomas Jefferson Insulin Infusion Protocol (CIIP-TJIIP) 
 NICE-SUGAR Protocol (CIIP-NS) 
We used the same data from our previous study in Aim 1 (18,984 eProtocol-insulin 
recommendations with its associated data from 408 patients). We reported the statistical 
results of the recommended continuous IV insulin infusion rates when blood glucose was 
measured at time=ti from all six computer-based insulin infusion protocol candidates (see 
Table 4.8).  
We plotted the distributions of the recommended continuous IV insulin infusion rates 
by all six computer-based insulin infusion protocol candidates (see Figure 4.4). They 
appeared clinically similar.  
We conducted the pairwise Wilcoxon signed rank test for all the computer-based 
insulin infusion protocol candidates (see Table 4.9). The majority of the pairwise 
comparison showed that the p-value was less than 0.0001. HWCIR Glucose Protocol and 
CIIP-AMC has p-value of 0.02. This p-value was still less than 5% (0.05 significance 




Table 4.8: Statistical results of recommended continuous IV insulin infusion rates by six 











Mean (U/h) 3.9 4.0 3.6 5.0 3.0 3.9 




2.7 3.1 2.8 5.9 2.6 2.6 
Minimum 
(U/h) 
0 0 0 0 0 0 
Maximum 
(U/h) 








Figure 4.4: Distributions of recommended continuous IV insulin infusion rate by six 





















NA < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 




  NA 0.02 < 0.0001 < 0.0001 
CIIP-
AMC 
   NA < 0.0001 < 0.0001 
CIIP-
TJIIP 
    NA < 0.0001 
CIIP-NS      NA 
 
 
protocols to be statistically different.  
We analyzed the favorability scoring using the ranking strategy as outlined in the 
methods section. We used a standard competition ranking strategy to assign the rankings 
to our computer-based insulin infusion protocol candidates. Ranking scores were converted 
to favorability scores using the Borda count formula. Scores were then calculated and 





Figure 4.5: Ranked favorability scores for six computer-based insulin infusion protocol 
candidates 
 
overall score, followed by CIIP-AMC and CIIP-TJIIP, respectively. eProtocol-insulin 
scored the lowest in the ranked favorability scoring.  
We stratified the ranked favorability scores by three blood glucose measurement 
categories at time=ti+1 (<80, 80-110, and >110 mg/dL) (see Figure 4.6). Glucosafe has the 
highest scores in the low (< 80 mg/dL) and high (> 110 mg/dL) blood glucose range. CIIP-
TJIIP scored the highest in the on-target blood glucose range. eProtocol-insulin scored the 
lowest in the low blood glucose range category. CIIP-SN scored the lowest in the on-target 
blood glucose range. CIIP-TJIIP scored the lowest in the high blood glucose range 
category. 
We calculated the median and interquartile range (IQR) for all six computer-based 
insulin infusion protocol candidates (see Table 4.10). The continuous IV insulin infusion 














Table 4.10: Continuous IV insulin infusion rate recommendations by six computer-based 






Continuous IV insulin infusion rate recommendation 













Low (< 80 
mg/dL) 

















High (> 110 
mg/dL) 




















4.2.2 Discussion for Aim 2 
We identified a major issue with the paired comparison method described in Aim 1 
where the comparison of multiple computer-based insulin infusion protocol candidates was 
burdensome especially when the number of candidates increases. Our solution was to 
implement a ranking strategy. We successfully compared six computer-based insulin 
infusion protocol candidates. Overall, Glucosafe was found to be the most favorable.  
The pairwise Wilcoxon signed rank test confirmed that the distribution of 
recommended continuous IV insulin infusion rate for all the computer-based insulin 
infusion protocol candidates was statistically different. The results indicated that the 
computer-based insulin infusion protocol candidates were intrinsically different. The 
internal system of the computer-based insulin infusion protocols reacted differently 
although they were subjected to the same input.  
The median for each of the computer-based insulin infusion protocol candidates at 
different blood glucose ranges was consistent with the ranked favorability scoring. At low 
blood glucose range, the highest ranked computer-based insulin infusion protocol 
candidate was Glucosafe with a median at 1.5 U/h. At on target blood glucose range, the 
highest ranked computer-based insulin infusion protocol candidate was CIIP-TJIIP with 
insulin infusion rate of 2.2 U/h. This was followed by Glucosafe with a median of 2.8 U/h. 
At high blood glucose range, the highest ranked computer-based insulin infusion protocol 
candidate was Glucosafe. Again, Glucosafe has the highest median value of 5.4 U/h. 
There were several advantages of using the ranking method over paired comparison. 
The ranking method was straightforward to deploy. It has helped to reduce the number of 




protocol candidates. Using the ranking scale, the computer-based insulin infusion protocol 
candidates were graded from best to worst based on the favorability of the continuous IV 
insulin infusion rate. Therefore, the results can be easily analyzed by healthcare 
practitioners. However, using just one set of evaluation criteria can limit the effort of 
evaluating the performances of computer-based insulin infusion protocol candidates. We 
often find multiple conflicting criteria when evaluating our options. Going forward, it was 
imperative that we take this into consideration when choosing the best available computer-
based insulin infusion protocol for a clinical trial. 
4.3 Aim 3 
4.3.1 Results for Aim 3 
The third aim of the study was to design a method of aiding our healthcare practitioners 
to choose the most appropriate computer-based clinical protocol for a clinical trial. We 
used multiple-criteria decision analysis to compare six of the computer-based insulin 
infusion protocol candidates to derive our decision. We selected seven criteria to analyze 
the performance of the computer-based insulin infusion protocol candidates. 
4.3.1.1 Ranked Favorability Scoring 
 We obtained the score from the ranked favorability scoring as described in the 
Methods for Aim 2. The computer-based insulin infusion protocol candidates were then 
assigned their rank according to the order of score (see Table 4.11). Glucosafe has the 




Table 4.11: Ranking of computer-based insulin infusion protocol candidates using 
criterion 1 (ranked favorability scoring) 





eProtocol-insulin 46,524 6 
Glucosafe 62,635 1 
HWCIR Glucose Protocol 52,580 4 
CIIP-AMC 54,429 2 
CIIP-TJIIP 53,403 3 
CIIP-NS 46,600 5 
 
4.3.1.2 Estimation of Hypoglycemia Rate 
We used the eProtocol-insulin observed rate of change of blood glucose per unit of 
insulin at time ti to estimate the subsequent blood glucose level for other computer-based 
insulin infusion protocols at time ti+1. An observation was marked as hypoglycemia if the 
estimated blood glucose was less than 60 mg/dL. The number of cases of hypoglycemia in 
eProtocol-insulin was the actual observations recorded. The results showed that CIIP-AMC 
has the highest estimated cases of hypoglycemia at 5.5% (see Figure 4.7). eProtocol-insulin 
has the lowest incidence of hypoglycemia.  
The computer-based insulin infusion protocol candidates were then assigned their rank 
according to the order of score obtained from the estimated cases of hypoglycemia (see 
Table 4.12). Lower percentage of cases of hypoglycemia was considered better. 
In another analysis (see Table 4.13), we pooled the number of cases with risk of 





Figure 4.7: Estimated cases of hypoglycemia (* represents actual cases). 
 
Table 4.12: Ranking of computer-based insulin infusion protocol candidates using 
criterion 2 (estimated cases of hypoglycemia) 
Computer-based insulin infusion 
protocol candidate 
Estimated cases of 
hypoglycemia (%) 
Rank 
eProtocol-insulin* 0.8 1 
Glucosafe 3.3 5 
HWCIR Glucose Protocol 1.3 3 
CIIP-AMC 5.5 6 
CIIP-TJIIP 1.0 2 








Table 4.13: Number of cases estimated to have risk of hypoglycemia stratified according 




More favorable computer-based insulin infusion protocol 
according to Favorability Scoring in Methods for Aim 1 but 
with risk of hypoglycemia 
 eProtocol-insulin Glucosafe Equivalent 
< 80 137 9 12 
80 - 110 231 0 38 
> 110 0 139 203 
Total 368 148 114 
 
 
was considered to be more favorable (see Methods for Aim 1, a pairwise comparison of 
Glucosafe and eProtocol-insulin using favorability scoring). This was an attempt to 
compare the findings in Methods for Aim 1 and Methods for Aim 3. We found 148 
estimated cases of hypoglycemia when Glucosafe was considered more favorable. 
However, there were 482 estimated cases of hypoglycemia when Glucosafe was not 
considered more favorable (see Table 4.13).  
4.3.1.3 Estimation of Hyperglycemia Rate 
We used the eProtocol-insulin observed rate of change of blood glucose per unit of 
insulin at time ti to determine the hyperglycemia rate by estimating the subsequent blood 
glucose level for other computer-based insulin infusion protocols at time ti+1. Observation 




The number of cases of hyperglycemia in eProtocol-insulin was the actual observations 
recorded. The results showed that CIIP-AMC has the highest estimated cases of 
hyperglycemia at 5.6% (see Figure 4.8). eProtocol-insulin has the lowest incidence of 
hyperglycemia at 3.2%.  
The computer-based insulin infusion protocol candidates were then assigned their rank 
according to the order of score obtained from the estimated cases of hyperglycemia (see 
Table 4.14). Lower percentage of cases of hyperglycemia was considered better. 
4.3.1.4 Estimation of Cases Within the Target Range 
We used the eProtocol-insulin observed rate of change of blood glucose per unit of 
insulin at time ti to estimate the subsequent blood glucose level for other computer-based 
insulin infusion protocols at time ti+1. An observation was marked as within target range if 
the estimated blood glucose was between 80 mg/dL and 110 mg/dL. The number of cases 
of blood glucose within the target range in eProtocol-insulin was the actual observations 
recorded. The results showed that CIIP-TJIIP has the highest estimated cases of blood 
glucose within the target range at 52.3% (see Figure 4.9). HWCIR Glucose Protocol has 
the lowest incidence of cases where the blood glucose was within the target range.  
The computer-based insulin infusion protocol candidates were then assigned their rank 
according to the order of score obtained from the estimated cases of blood glucose within 







Figure 4.8: Estimated cases of hyperglycemia (* represents actual cases). 
 
Table 4.14: Ranking of computer-based insulin infusion protocol candidates using 
criterion 3 (estimated cases of hyperglycemia) 
Computer-based insulin infusion 
protocol candidate 
Estimated cases of 
hyperglycemia (%) 
Rank 
eProtocol-insulin* 3.2 1 
Glucosafe 4.6 5 
HWCIR Glucose Protocol 3.3 2 
CIIP-AMC 5.6 6 
CIIP-TJIIP 3.6 3 






Figure 4.9: Estimated cases of blood glucose within the target range (* represents actual 
cases). 
 
Table 4.15: Ranking of computer-based insulin infusion protocol candidates using 
criterion 4 (estimated cases of blood glucose within the target range) 
Computer-based insulin infusion 
protocol candidate 
Estimated cases 
within the target 
range (%) 
Rank 
eProtocol-insulin* 49.3 3 
Glucosafe 51.9 2 
HWCIR Glucose Protocol 45.9 6 
CIIP-AMC 48.0 5 
CIIP-TJIIP 52.3 1 





4.3.1.5 Mean of Recommended Continuous IV Insulin Infusion Rates 
We measured the mean of recommended continuous IV insulin infusion rates for each 
of the computer-based insulin infusion protocol candidates (see Figure 4.10). We stratified 
the results according to five blood glucose range categories at time=ti: 
 Less than 60 mg/dL 
 Less than 80 mg/dL 
 80-110 mg/dL 
 Greater than 110 mg/dL 
 Greater than 180 mg/dL 
At very low blood glucose range (< 60 mg/dL), all of the computer-based insulin 
infusion protocols recommended none or very little insulin for patients. At low blood 
glucose range (< 80 mg/dL), the highest average recommended continuous IV insulin 
infusion rate was eProtocol-insulin (mean=2.7 U/h). HWCIR Glucose Protocol did not 
recommend any insulin when blood glucose was below 80 mg/dL.  
When blood glucose was within the target range, the highest average recommended 
continuous IV insulin infusion rates were eProtocol-insulin (mean=3.7 U/h), HWCIR 
Glucose Protocol (mean=3.7 U/h), and CIIP-NS (mean=3.7 U/h). The lowest average 
recommended continuous IV insulin infusion rate was CIIP-TJIIP (mean=2.5 U/h).  
At high blood glucose range (> 110 mg/dL), CIIP-AMC has the highest average 
recommended continuous IV insulin infusion rate (mean=7.9 U/h) followed by Glucosafe 
(mean=6.3 U/h). The lowest average recommended continuous IV insulin infusion rate in 
the high blood glucose range was CIIP-TJIIP (mean=4.0 U/h). 





Figure 4.10: Mean of recommended continuous IV insulin infusion rates 
 
recommended continuous IV insulin infusion rate (mean=11.0 U/h) followed by Glucosafe 
(mean=9.1 U/h). The lowest average recommended continuous IV insulin infusion rate in 
the high blood glucose range was HWCIR Glucose Protocol (mean=5.2 U/h).  
The computer-based insulin infusion protocol candidates were then assigned their rank 
according to the amount of recommended continuous IV insulin infusion rate at each blood 
glucose range category (see Table 4.16). At very low (< 40 mg/dL), low (< 60 mg/dL), and 
within target range (80-110 mg/dL) categories, we preferred lower measure of mean for 
recommended continuous IV insulin infusion rate. At high (> 110 mg/dL) and very high 
(> 180 mg/dL) blood glucose range categories, we preferred higher measure of mean for 
recommended continuous IV insulin infusion rate. 
The ranks were summed up and overall ranking was recalculated based on the total in 
ranks (see Table 4.16). The results indicated that CIIP-AMC has the highest rank for mean  




Table 4.16: Ranking of computer-based insulin infusion protocol candidates using 
























































< 60 1 6 1 1 5 1 
< 80 6 2 1 3 4 5 
80-110 5 2 6 3 1 4 
> 110 5 2 4 1 6 3 
> 180 4 2 6 1 5 3 
Total in 
Ranks 21 14 18 9 21 16 
Overall 







shared the lowest rank for the mean measure.  
4.3.1.6 Median of Recommended Continuous IV Insulin Infusion Rates 
We measured the median of recommended continuous IV insulin infusion rates for 
each of the computer-based insulin infusion protocol candidates (see Figure 4.11). We 
stratified the results according to five blood glucose range categories at time=ti: 
 Less than 60 mg/dL 
 Less than 80 mg/dL 
 80-110 mg/dL 
 Greater than 110 mg/dL 
 Greater than 180 mg/dL 
At very low blood glucose range (< 60 mg/dL), the median for all of the computer-
based insulin infusion protocols was zero. At low blood glucose range (< 80 mg/dL), the 
highest median for recommended continuous IV insulin infusion rate was eProtocol-insulin 
(median=2.2 U/h). HWCIR Glucose Protocol has a median of zero when blood glucose 
was below 80 mg/dL.  
When blood glucose was within the target range, the highest median for recommended 
continuous IV insulin infusion rates were eProtocol-insulin (median=3.2 U/h) and HWCIR 
Glucose Protocol (median=3.2 U/h). The lowest median for recommended continuous IV 
insulin infusion rate was CIIP-TJIIP (median=2.0 U/h).  
At high blood glucose range (> 110 mg/dL), the highest median for recommended 
continuous IV insulin infusion rate was Glucosafe (median=6.2 U/h) followed by CIIP-





Figure 4.11: Median of recommended continuous IV insulin infusion rates 
 
infusion rate in the high blood glucose range was CIIP-TJIIP (median=3.4 U/h). 
At very high blood glucose range (> 180 mg/dL), the highest median for recommended 
continuous IV insulin infusion rate at this blood glucose range was Glucosafe (median=8.8 
U/h) followed by CIIP-AMC (median=6.0 U/h). The lowest median recommended 
continuous IV insulin infusion rate was CIIP-TJIIP (median=4.1 U/h). 
The computer-based insulin infusion protocol candidates were then assigned their rank 
according to the median results at each blood glucose range category (see Table 4.17). At 
very low (< 40 mg/dL), low (< 60 mg/dL), and within target range (80-110 mg/dL) 
categories, we preferred lower median for recommended continuous IV insulin infusion 
rate. At high (> 110 mg/dL) and very high (> 180 mg/dL) blood glucose range categories, 
we preferred higher median for recommended continuous IV insulin infusion rate. 
The final results showed that Glucosafe was ranked first using the median criterion 




Table 4.17: Ranking of computer-based insulin infusion protocol candidates using 

























































< 60 1 1 1 1 1 1 
< 80 6 2 1 3 4 5 
80-110 5 2 5 2 1 4 
> 110 4 1 4 2 6 3 
> 180 4 1 5 2 6 3 
Total in 
Ranks 20 7 16 10 18 16 
Overall 
ranking 6 1 3 2 5 3 
 
 
and eProtocol-insulin.  
4.3.1.7 Distributed Favorability Scoring 
We estimated the subsequent blood glucose for all computer-based insulin infusion 
protocol candidates and assigned them the score accordingly. The scores were then 
summed up (see Figure 4.12).  





Figure 4.12: Distributed favorability scoring 
 
according to the order of score obtained from the distributed favorability scoring (see Table 
4.18). Higher score for distributed favorability was considered better. 
Our results showed that CIIP-TJIIP attained the highest rank in distributed favorability 
scoring, followed by eProtocol-insulin and CIIP-NS. 
4.3.2 Aggregating Decision Scores 
We measured the quality of our computer-based insulin protocol candidates by 
considering the seven criteria described above (see Methods section 3.7.2) using multiple-
criteria decision analysis. The criteria weights were arbitrarily assigned based on heuristic 
as an example. Scores for each of the criteria were calculated by multiplying the weight 
and ranks obtained earlier (see Table 4.19). 
Finally, the scores were aggregated and ready to be presented to the healthcare 




Table 4.18: Ranking of computer-based insulin infusion protocol candidates using 
criterion 7 (distributed favorability scoring) 





eProtocol-insulin 1,489,580 2 
Glucosafe 1,462,000 4 
HWCIR Glucose Protocol 1,446,850 5 
CIIP-AMC 1,399,350 6 
CIIP-TJIIP 1,511,830 1 
















Table 4.19: Scores using multiple-criteria decision analysis with seven criteria to measure 
computer-based insulin infusion protocols (*higher score is better). 
Criteria Weight 































































48 16 40 8 32 24 
Estimation of cases 
within the target range 
7 
28 35 7 14 42 21 
Mean of recommended 
continuous IV insulin 
infusion rates 
5 
10 25 15 30 10 20 
Median of recommended 
continuous IV insulin 
infusion rates 
3 










Figure 4.13: Aggregated score using multiple-criteria decision analysis (*higher score is 
better). 
 
example, followed by Glucosafe and eProtocol-insulin. We did not evaluate the impression 
of healthcare practitioners using the multiple-criteria decision analysis. 
4.3.3 Discussion for Aim 3 
We have successfully developed an in silico method with increasingly sophisticated 
and informative techniques to help our healthcare practitioners make an informed decision 
about choosing the most appropriate computer-based insulin infusion protocol for a clinical 
trial. We believed the seven criteria that we have developed for the multiple-criteria 
decision analysis were critical in evaluating the performance of these computer-based 
insulin infusion protocol candidates.  
The ranked favorability scoring (criterion 1) analyzed the perceived favorability of 
each candidate by comparing the relative goodness of the recommended insulin infusion 




this category. Glucosafe consistently gave more favorable recommended insulin infusion 
rates compared to others.  
In some cases, the amount of recommended insulin infusion rate by a certain 
computer-based insulin infusion protocol candidate can cause a greater drop in blood 
glucose level even though their overall favorability gave us a good score. By estimating 
the hypoglycemia rate (criterion 2), we were able to calculate the risk of hypoglycemia that 
may occur with the use of that computer-based insulin infusion protocol. CIIP-AMC has 
the highest estimated rate of hypoglycemia. Healthcare practitioners may decide not to 
choose this computer-based insulin infusion protocol if the risk of hypoglycemia is a major 
concern solely based on this criterion.  
If the amount of recommended insulin infusion rate by a certain computer-based 
insulin infusion protocol candidate was less than optimal, the blood glucose level may not 
drop to the desired level or may continue to increase. We were able to estimate the risk of 
hyperglycemia (criterion 3) by calculating the subsequent blood glucose level for 
computer-based insulin infusion protocols at time ti+1 and flagged the blood glucose levels 
that were greater than 180 mg/dL. CIIP-AMC has the highest estimated rate of 
hyperglycemia at 5.6% followed by Glucosafe at 4.6%. The rates were still clinically low 
compared to the actual cases measured by eProtocol-insulin at 3.2%. However, healthcare 
practitioners might be less likely to choose these computer-based insulin infusion protocols 
if this was the only criterion available.  
The estimation of cases within the target range (criterion 4) showed healthcare 
practitioners how consistently the computer-based insulin infusion protocols were able to 




target range among the computer-based insulin infusion protocol candidates appeared 
clinically similar (45.9% to 52.3%, range difference was 6.4%). CIIP-TJIIP has the highest 
number of cases estimated to be within the target range of 80-110 mg/dL, followed by 
Glucosafe.  
The mean and median measurement gave us a sense of the typical value of a computer-
based insulin infusion protocol candidate in question. By stratifying the results according 
to five blood glucose range categories, we were able to understand the performance of the 
computer-based insulin infusion protocol candidates during these key moments of low, on-
target, and high blood glucose range. The results showed that the mean and median values 
were fairly similar clinically. There were some notable differences at the high blood 
glucose range, in particular for Glucosafe and CIIP-AMC. CIIP-AMC has a higher mean 
but lower median when compared to Glucosafe. This indicated that CIIP-AMC tends to 
recommend higher insulin infusion rates more frequently than Glucosafe. At low blood 
glucose range, HWCIR performed exceptionally well because the protocol will not 
recommend any continuous IV insulin infusion when blood glucose level falls below 80 
mg/dL. When blood glucose was within the target range, CIIP-TJIIP has the lowest mean 
and median values. Thus, CIIP-TJIIP was regarded as having a much better performance 
compared to other computer-based insulin infusion protocol candidates because not only 
was it able to maintain the blood glucose within the desirable level, lower insulin infusion 
rate may prevent cases of hypoglycemia. At high blood glucose range, we have mixed 
results due to the mean and median values, but overall, Glucosafe and CIIP-AMC did well 
in this regard. However, Glucosafe was more consistent when recommending higher 




The goal of the distributed favorability scoring was to analyze how well the computer-
based insulin infusion protocol candidate manages the patient’s blood glucose. Higher 
scores were given if their estimated blood glucoses were closer to the desired target range. 
CIIP-TJIIP has the highest aggregated score among the computer-based insulin infusion 
protocol candidates. This also means that CIIP-TJIIP was able to tightly control the blood 
glucose levels.  
We found that CIIP-TJIIP was the overall winner of the multiple-criteria decision 
analysis. The CIIP-TJIIP has the highest rank for the estimated number of cases within the 
target range and distributed favorability scoring, and a fairly low estimated rate of 
hypoglycemia. This may have been largely contributed by the higher target blood glucose 
range (100-140 mg/dL) set by the rules of the protocol. Glucosafe was a close second in 
the multiple-criteria decision analysis despite having scored less for estimated 
hypoglycemia and hyperglycemia rate. Nevertheless, healthcare practitioners who prefer a 
computer-based insulin infusion protocol that matches their target range of 80-110 mg/dL 
may want to consider Glucosafe for their clinical trial instead.  
In a separate analysis, we compared the findings in Methods for Aim 1 (pairwise 
comparison of Glucosafe and eProtocol-insulin using favorability scoring) and Methods 
for Aim 3 (estimated cases of hypoglycemia). While some may expect that Glucosafe 
continues to have relatively low risk of hypoglycemia because of how well it performed in 
the favorability scoring in Methods for Aim 1, the result predicted more instances of 
Glucosafe recommending insulin doses that could have a high risk of hypoglycemia (482 
instances when Glucosafe was not favorable versus 148 instances when Glucosafe was 




one criterion (using relative recommended insulin dose to measure favorability) is simply 
not adequate to get an overview for the performance of a computer-based clinical protocol 
candidate. Protocols have complex influences, and effects are multifactorial; there are often 
trade-offs between meeting one goal (e.g., quickly getting blood glucose reduced to the 
target range), and other goals or risks (e.g., likelihood of blood glucose continuing to fall 
past the target range, causing hypoglycemia).  
While all of the criteria described above were different, each of them was able to probe 
different aspects of the computer-based insulin infusion protocol candidates and illuminate 
their strengths and weaknesses. This is the main difference between the multiple-criteria 
decision analysis (Methods for Aim 3) and single criteria analysis (Methods for Aim 1 and 
Methods for Aim 2). While results from the single criteria analysis may have suggested 
that Glucosafe was the better candidate, an in-depth analysis using multiple-criteria 
decision analysis revealed otherwise. A high favorability scoring (as suggested in Methods 
for Aim 1 and Methods for Aim 2) does not guarantee high scoring for performance criteria 
such as estimated rate of hypoglycemia. While Glucosafe recommended more favorable 
continuous IV insulin infusion rates, some of the unfavorable infusion rates may be 
harmful. The other probes suggested in Methods for Aim 3 can illuminate these issues more 
effectively. The aggressive approach with Glucosafe may affect patients in terms of 
extreme blood glucose management (hypoglycemia and hyperglycemia) if healthcare 
practitioners do not have the resources to monitor the bedside situation more closely. 
The final results may still vary depending on the weights of the evaluation criteria and 
blood glucose target selected by healthcare practitioners during the preclinical trial 




importance they place based on their patient’s needs or clinical situations. For example, 
pediatricians may decide that avoiding the risk of hypoglycemia for patients in the pediatric 
ICU is more important than how efficient the insulin brings down the high blood glucose 
level. In some practice, healthcare practitioners may decide that a different blood glucose 
target range, e.g. 90-140 mg/dL, is better for their patients. This can change the outcome 
because many of these criteria are affected by the choice of blood glucose target range. 
In this study, the weights were assigned arbitrarily as an example to showcase the 
multiple-criteria decision analysis. While this was not the scope of the study, we believe 
that more robust weights should be obtained through healthcare practitioners involved in 
the evaluation. We will need to measure the degree of agreement among the raters through 
a form of interrater reliability measure such as Cohen’s kappa. Such measurement can be 
useful to examine for any variability in the ratings and lend crediability to the weights.  
Multiple-criteria decision analysis can be susceptible to changes due to the decision-
making environment. Each step in the decision-making process involves some form of 
uncertainty. This includes the selection of analytical method, choice of criteria, assessment 
of the values of the criteria, and choice of weights. A sensitivity analysis can help us test 
the robustness of the results from the multiple-criteria decision analysis in the presense of 
all these uncertainties. We will need to determine the amount of changes in the criterion 
weight that would affect the rank outcome of the computer-based insulin infusion protocols 
in the multiple-criteria decision analysis. One may think that the larger weight may have a 
significant change in the analysis. However, it may be possible that criteria with small 
weights can be critical when influencing the final result of the analysis. Thus, a sensitivity 




investigated to ensure successful implementation of the evaluation strategy. 
Our physiological process simulation in the in silico framework was based on the 
notion that patients who had been intervened with the computer-based insulin infusion 
protocol (in this case eProtocol-insulin) creates the necessary simulation for comparison 
with other computer-based insulin infusion protocols. We reasoned that such patient data 
provide the best representation of a treatment plan and the patient response to the 
intervention. We therefore assumed that patients intervened with eProtocol-insulin can re-
create all the necessary blood glucose-insulin interactions if we have sufficient data in the 
simulation. In the absence of data for these patients who had been intervened with similar 
computer-based insulin infusion protocols, we may be able to recreate the physiological 
process simulation using wild type data where patients were treated with paper protocols 
or healthcare practitioners heuristics. 
The multiple-criteria decision analysis was key in summarizing the performance of 
computer-based insulin infusion protocol candidates. The performance scores provided key 
insights and necessary clarity into the inner workings of the system. The analysis can also 
help healthcare practitioners set the right expectations and avoid potential issues when 
assessing the computer-based insulin infusion protocol in an actual clinical trial.   
  
5 CONCLUSION 
Clinical protocols are often used to make patient care better linked to best evidence. 
The advancement of medical knowledge and computerization has brought many benefits 
to healthcare. However, rapid development of healthcare systems has also spurned many 
versions of computer-based clinical protocols that were developed using different 
standards of practice and medical knowledge. How do we evaluate these clinical protocols? 
How do we compare and identify computer-based clinical protocols that will meet our care 
standards and be suitable for our clinical trial? These were the questions that first motivated 
our research in this field. A healthcare practitioner can spend time going through the 
manuals, rule sets, or mathematical algorithms describing the physiology behind the 
computer-based clinical protocols. Yet they may barely understand how all of these will 
impact their patients. Our in silico method enabled us to create a framework for comparing 
and evaluating computer-based clinical protocols by simulating patient care with these 
protocols. We have successfully demonstrated our in silico method using EMR data. We 
used wide ranging techniques to evaluate six computer-based insulin infusion protocols 






5.1 Strengths and Limitations 
There were many advantages to our in silico approach to compare and evaluate 
computer-based insulin infusion protocols. First, the in silico method was an inexpensive 
approach to identify a computer-based insulin infusion protocol without incurring the full 
cost of a clinical trial. The comprehensive analysis can be performed in a computer 
simulation without any intervention by healthcare practitioners. This has the potential to 
reduce the cost of healthcare in general. Second, the in silico method performed various 
simulations in a safe environment without involving real patients. Patients were not 
exposed to any risk when we investigated critical scenarios with our in silico method. 
Third, the in silico method has encouraged healthcare practitioners to get more involved in 
the development and evaluation of computer-based insulin infusion protocols. It enhanced 
collaboration between technical developers and healthcare providers. Participation of 
healthcare practitioners in the evaluation process can lead to better satisfaction and 
acceptance towards the use of computer-based clinical protocols in practice. Fourth, results 
from the in silico method can be used to improve future iterations of the computer-based 
insulin infusion protocols. Researchers can use these results to address issues in the system 
and to tweak the performance of the computer-based insulin infusion protocol accordingly. 
We have several limitations to our study. Our population sample was limited to Utah 
adult patients who were primarily Caucasians of northern European descent. The lack of 
diversity may have hampered the generalizability of the results to populations of other 
ethnicity. Studies have shown that there may be relations between insulin resistance and 
sensitivities among racial groups [104,105]. Our research data were generated with patients 




comparison of computer-based insulin infusion protocol candidates using clinical data 
generated with computer-based insulin infusion protocols other than eProtocol-insulin 
might be useful. 
We were limited by the data that we used as inputs to our computer-based insulin 
infusion protocol candidates. While these data sets were adequate to generate reasonable 
continuous IV insulin infusion recommendations, additional data such as medications, 
hypertension, and types of infection may provide valuable insights.  
We eliminated a large number of records with certain imperfections because we 
wanted to maximize the validity of our comparative results. However, doing so may have 
affected the generalizability of our evaluation towards other computer-based insulin 
infusion protocol candidates. It is possible that the patient records that were excluded may 
reflect clinical conditions that would have altered our findings. However, the demographic 
characteristics of the patients in the retained records appear to be reflective of the 
demographic characteristics in the ICUs.  
We found apparently contradictory results from our different methods, with different 
protocols emerging as the winner depending on what comparison method we chose. In 
addition, the weights that were used in our final evaluation were chosen heuristically by 
the investigators and may not be reflective of the weights that clinicians may actually 
choose in practice – the results of that evaluation may be different had different criteria 
been used. However, the results demonstrated that the framework is capable of 





Results must be reproducible before they are accepted in any scientific domain. These 
results often require experimental methods that can be replicated with clinical decision-
making methods. We believe consistent clinical decision-making methods can be enabled 
by using computer-based clinical protocols. It can standardize the process of care and 
eliminate unnecessary variations in clinical practice.  
We have demonstrated that our in silico method was applicable to different types of 
computer-based insulin infusion protocols. Even though they were developed using 
different knowledge base and scientific details (rule-based, physiologic mathematical 
modeling, statistical models, and column-based charts), the framework allowed multiple 
comparison and evaluation of these computer-based insulin infusion protocols possible. 
While we only focused our research on one type of computer-based clinical protocol, we 
believe the framework for our in silico method can be extended to compare and evaluate 
other types of computer-based clinical protocols such as mechanical ventilator protocols 
and warfarin management protocols.  
5.3 Suggestions for Future Research 
Future research may involve exploring more subtle favorability scoring algorithms that 
could analyze delicately complex patients’ outcome. This may include blood glucose 
trends over a period of time, interaction with medications, diet, impact on patient’s blood 
glucose due to insulin resistance, and insulin sensitivity to different ethnicity groups. These 
algorithms can add more contrast to the existing ones and help evaluate performance 
criteria that have not been adequately examined previously.  




of eProtocol-insulin. We only used a subset of EMR data such as nutrition and use of 
Propofol as input to our computer-based insulin infusion protocol candidates. Going 
forward, future computer-based insulin infusion protocol candidates may require more 
extensive clinical observations and historical data for their recommendations. These may 
include genetic factors, family history, hypertension, triglyceride levels, types of infection, 
and various medications (glucosamine, rifampicin, corticosteroids, glucocorticoids, 
methadone, antiretrovirals, etc.) 
We believe our next generation of in silico methods will have more sophisticated 
computer simulation to simulate realistic patients’ response to insulin intervention. The in 
silico methods will need to be able to incorporate clinical usage patterns including time 
variation so that they will closely mimic the use of a computer-based insulin infusion 
protocol at the bedside.  
We can continue to enhance our glucose-insulin regulation models by incorporating 
more sophisticated techniques such as machine learning and probabilistic methods. Since 
our focus in this initial study was not about developing more advanced models, we chose 
a simple linear model to describe the relationship between insulin dosage and change in 
blood glucose. We can continue to incorporate more complex mathematical models in our 
computer simulation to investigate their usefulness. We will also need to validate these 
models in clinical studies to verify the accuracy and generalizability of these models. Going 
forward, we believe machine learning techniques such as deep learning will become 
particularly important when we are able to gather huge amounts of data.  
One critical enhancement to the in silico framework will be interoperability. There has 




different types of computer-based insulin infusion protocols. This is important because 
many computer-based insulin infusion protocols are built on different platforms for specific 
users or systems in a particular healthcare institution. A patient model can help map the 
various inputs and outputs of the computer-based insulin infusion protocol with the 
structure of the computer simulation. The in silico framework also has to support a common 
structure for exchanging information between the computer simulation and the computer-
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